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ABBREVIATIONS 
 
  
aa Amino acid 
Aβ Amyloid-β peptide 
AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
AICD APP intracellular domain 
APH-1 Anterior pharynx-defective phenotype 
APLP APP like protein 
APP β-amyloid precursor protein 
APS Ammonium persulfat 
BACE β-site APP-cleaving enzyme 
BSA Bovine serum albumin 
CD44 Cluster of differentiation 44 
CD44β CD44 beta peptide 
CD44-ICD CD44 intracellular domain 
C.elegans Caenorhabditis elegans 
CHAPSO 3-[(3-cholamidopropyl)dimethyl-ammonio]-2-
hydroxy-1-propanesulfonate 
CTF C-terminal fragment 
DDM n-dodecyl-D-maltoside 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
DTT 1,4 Dithiothreitol 
E.coli Escherichia coli 
EDTA Ethylene diamine tetraacetic 
EGFR Epidermal-growth-factor-receptor 
ER Endoplasmic reticulum 
FAD Familial AD 
Fen Fenofibrate 
F-NEXT Flag tagged NEXT 
Flu Flurbiprofen 
GSM γ-Secretase modulator 
HEK Human embryonic kidney cells 
HOP-1 Homologue of PS 
ICD Intracellular domain 
IL1R2 Interleukin1 receptor type II 
IP Immunoprecipitation 
kDa Kilodalton 
MEF Mouse embryonic fibroblast 
MMP Membrane-associated matrix metalloproteinase 
MS Mass spectrometry 
Nap Naproxen 
Nβ Notch beta peptide 
NCT Nicastrin 
NEXT Notch extracellular truncation 
NICD Notch intracellular domain 
NSAID Non-steroideal anti-inflammatory drug 
NTF N-terminal fragment 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffer saline 
PCR Polymerase chain reaction 
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PEN-2 PS enhancer 2 
PS Presenilin 
RNA Ribonucleic acid 
RNAi RNA interference 
SAP Shrimp alkaline phosphatase 
S1,S2,S3,S4 Site 1, site 2, site 3, site 4 
sAPP Soluble APP 
sCD44 Soluble CD44 
SDS Sodium dodecyl sulfate  
SEL-12 Suppressor / enhancers of lin-12 
SPE-4 Spermatogenesis defective-4 
SPP Signal peptide peptidase 
SPPL SPP like protein 
Sul Sulindac sulfide 
sw Swedish mutant 
TBS Tris buffer saline 
TEMED N,N,N’,N’-tretramethylethylethylendiamine 
TFPP Type 4 prepilin peptidase 
TNF-α Tumor necrosis factor-α 
wt Wild type 
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1 Introduction 
 
1.1 Alzheimer’s disease 
 
Alzheimer’s disease (AD), named after the german psychiatrist Alois Alzheimer (figure 1), 
is the most common neurodegenerative dementia observed in people older than 65 years 
in the world and is expected to affect to ~16 million cases in the year 2050 in Europe (1). 
About 100 years ago Alzheimer described delusions, hallucinations, dementia, 
disorientation and loss of memory, as the clinical symptoms of the disease suffered by the 
51 years old Auguste D. (figure 1) the first reported AD patient. Neuropathological post-
mortem studies of her brain by silver staining identified neuritic plaques and neurofibrillary 
tangles (2) as the two principal hallmarks of the disease. 
 
                    
Figure 1. Photographs of Alois Alzheimer (left) and the first documented AD patient, Auguste D. 
(right).  
 
 
 
Nowadays, using electron microscopy or immunohistochemical staining for synaptic 
markers has shown a decrease in the synaptic density in the AD brain (3,4). Moreover, 
the decrease in the synapse number is deproportionated to the loss of neurons. This 
suggests that the loss of synaptic endings precedes the demise of the neurons leading to 
the cognitive impairment, which is the major hallmark in AD.  
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Biochemical analysis showed that the neurofibrillary tangles present in AD brain, that 
occupy much of the perinuclear cytoplasm, are made of abnormal filaments, the so-called 
paired helical filaments (PHF). These have a diameter of 10 nm, and are formed by a 
hyperphosphorylated form of the microtubule-associated protein tau (5). The physiological 
role of tau is probably the stabilization of axonal microtubuli by bridging and stabilizing the 
tubulin-tubulin interfaces along protofilaments (6,7) but in AD, hyperphosphorylation of tau 
leads to its dissociation from the microtubules and aggregation into PHFs (8) (figure 2) 
perturbing probably the cell’s transport machinery. 
 
The second pathological hallmark in AD brain are neuritic plaques, which are generally 
found in the limbic and association cortices (9). These plaques contain extracellular 
deposits of amyloid-β (Aβ) peptide (10,11) and are surrounded by activated microglia and 
astrocytes (12) (figure 2). These amyloid plaques are composed of heterogeneous ~4 kDa 
Aβ peptide species derived from the amyloid precursor protein (APP) (13,14) (mainly 
Aβ38, Aβ40, Aβ42, Aβ43) and contain the highly aggregation-prone Aβ42 as predominant 
constituent (15,16). Short N-terminal truncated species have also been found in the 
amyloid plaques (17). 
 
 
                                        
 
Figure 2: AD neuropathology as revealed by silver staining. Aβ containing plaques (green asterisk) 
and neurofibrillary tangles (blue head arrows). 
 
 
Large Aβ plaques have been associated with local synaptic abnormalities even with the 
breakage of neuronal processes (18) but recent studies have also shown that small Aβ 
oligomers, dimers and trimers of Aβ, block hippocampal long-term potentiation, a measure 
of synaptic plasticity, in vivo (19). This block in the long-term potentiation reduces the 
density of dendritic spines and number of electrophysiologically active synapses thus 
interfering with the memory of a learned behavior in healthy adult rats (20,21). This 
*
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suggests that Aβ oligomers might play an important role in AD pathogenesis. The large Aβ 
aggregates could actually be inert or even protective to neurons by reducing the amount 
of the soluble Aβ oligomers as it has been proposed for other protein-folding disorders as 
for example in Huntington's disease (22). Nevertheles, large Aβ plaques, as mentioned 
above, have been associated with local synaptic abnormalities. Whether the large 
insoluble Aβ aggregates or the Aβ oligomers are the cause of AD is currently under 
debate. 
 
From these three hallmarks in AD, decrease in synaptic density, neurofibrillary tangles, 
and amyloid plaques, it is the number of neurofibrillary tangles which correlates better with 
the severity of the dementia than the number of amyloid plaques, although the best 
correlation occurs between measurements of synaptic density and degree of dementia 
(23,24).  
 
 
1.2 Genetics of Alzheimer’s disease  
 
The main risk to develop AD is aging. Most of the AD cases registered worldwide are not 
causally linked to a genetic factor and these cases are called “sporadic” AD. Although 
sporadic AD counts for most of the AD cases, the reason for it is still unclear. Sporadic AD 
may be caused by a decrease in the clearance of the Aβ peptide from the extracellular 
space by the Aβ degrading proteases insulin degrading enzyme (IDE) and neprylisin 
(25,26) or by an increase of β-secretase cleavage due to an increase in β-secretase 
expression (27).  
 
The genetically linked AD cases (familial AD, FAD) have a prevalence of ~5% of all AD 
cases, and manifest with an earlier age of onset (~ 60 years old) than the “sporadic” AD 
cases (28). 
 
Mutations in the β-amyloid precursor protein (APP), presenilin 1 (PS1) and presenilin 2 
(PS2) genes have been identified as the genetic causes of FAD (29-32). Most of the 
mutations, if not all, in these genes lead to larger production in Aβ42 species, which are 
more prone to aggregation (33,34) changing the ratio between Aβ42/Aβ40. 
 
Mutations in the APP are placed near its processing sites leading to AD by altering its 
proteolytic processing (figure 3) (see section 1.3.1.2). APP is processed by three 
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proteases termed α-secretase, β-secretase and γ-secretase (figure 5 and figure 6 and 
section 1.3.2). Mutations near the γ-secretase cleavage site increase the production of 
Aβ42 (35) whereas the mutations near the β-secretase cleavage site increase the 
production of both Aβ40 and Aβ42. This is the case of the rare Swedish APP mutation 
where two amino acids, KM are mutated to NL (36,37). Mutations within the Aβ domain, 
near the α-secretase site, increase the aggregation properties of the Aβ peptides 
generated (38). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of FAD mutations in APP. The amino acid sequence of the Aβ 
domain is enlarged. Arrows indicate the position of the α, β and γ-secretase cleavage sites. FAD 
mutations are displayed in purple. 
 
 
 
The APP gene is located on chromosome 21 (13,14,39,40). Interestingly, patients with 
trisomy 21 (Down syndrome) also develop AD neuropathology during middle adult years. 
The vast majority of Down patients often display plaques composed of Aβ42 in their 
adolescence (41). Microgliosis, astrocytosis as well as neurofibrillary tangles appear in the 
late 20s or 30s and progressive loss of cognitive functions after the age of 35 (41,42). 
Recently, it has also been discovered that an extra copy of the APP gene causes FAD, 
further supporting the hypothesis that increased Aβ production is the cause of the disease 
(43). 
 
Mutations in the PS1 and PS2 genes, located on chromosome 14 and 1 respectively, 
increase the ratio Aβ42/Aβ40 (44-51). More than 150 FAD mutations have been described 
in PS1 and 11 mutations in PS2 (Source:http://www.molgen.ua.ac.be/ADMutations/). The 
N-terminus C-terminus
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mutations occurs through the entire PS molecule (figure 4) and lead to a miscleavage of 
the APP substrate increasing the ratio of Aβ42 to Aβ40 (46,49) suggesting that PS 
mutations change the mode of APP processing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic depiction of a selection of FAD-associated mutations occurring in PS1 and 
PS2. Arrows indicate the location of the FAD mutations, which occur in the entire molecule. FAD-
associated PS2 mutations are depicted in italics. TM: Transmembrane domain; HL: Hydrophilic 
loop.  
 
 
 
 
The major genetic risk factor for late-onset AD is the ε4 allele of apolipoprotein E (52). 
This allele is present in subjects with AD and its inheritance may increase the risk of 
developing AD to above fivefold (28). The mechanism by which ApoE4 is related to AD is 
still unclear but ApoE4 protein has been found in Aβ deposits in AD brain tissue, so it 
might contribute to enhance Aβ deposition (28). However, a recent study has shown that 
ApoE4 plays a role in facilitating the proteolytic cleareance of soluble Aβ from the brain 
(53). 
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1.3 Molecular cell biology of Alzheimer’s disease 
 
1.3.1 Amyloid β precursor protein (APP) 
 
APP is a member of a family of conserved type I proteins that comprise the C.elegans 
APL-1 (54), Drosophila melanogaster APPL (55) and the mammalians APP like protein 1 
and 2 (APLP1 and APLP2) (56). 
 
The expression of APP and APLP2 is very similar. Both genes are strongly expressed in 
brain, kidney and lung, whereas the expression of APLP1 is much more restricted to the 
brain (57). APP is a 110 to 140 kDa protein (58), occurring in three major isoforms due to 
alternative splicing. These are referred to as APP695, APP751 and APP770 splice 
variants according to the number of residues (59,60). The 751 and 770 splice variants are 
expressed in both neuronal and non-neuronal cells while the 695 variant is predominantly 
expressed in neurons (61). Apart from their different tissue expression, another difference 
between these splice variants is that the splice variant 695 lacks the 56 amino acid Kunitz-
type serine protease inhibitor domain (60). 
 
 
The physiological function of APP is still unclear. Studies in mice that lack APP showed 
that these mice are viable and fertile (62). Aged mice deficient in APP are smaller than 
wild type mice and show impairment in behaviour and long-term potentiation (62,63). The 
subtle phenotype of APP deficient mice can indicate the compensation for the loss of APP 
by the presence of other APP family members. Indeed this is the case, whereas the mice 
deficient for APLP1 and APLP2 showed no major phenotype, the double knockout mice 
APP/APLP2 and APLP1/APLP2 lead to death shortly after birth. On the other hand, 
APP/APLP1 mice are viable (64,65). These data suggest a key physiological role for 
APLP2 and indicate redundancy between APLP2 and both other family members (64,65). 
A recent study has suggested a critical function for APP for proper migration of neuronal 
precursors cells during the development of the mammalian brain (66).  
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1.3.1.1 APP processing 
 
APP is posttranslationally modified along its trafficking path through the secretory pathway 
(67) towards the plasma membrane. Full length APP is subjected to sequential cleavages 
mediated by α-, β- and γ-secretases (section 1.3.2 and 1.3.3). These sequential 
cleavages give rise to two different processing pathways of APP. 
 
In the amyloidogenic pathway (figure 5), full length APP is first cleaved within its 
ectodomain by β-secretase. This cleavage, releases a soluble fragment called soluble 
APP-beta (sAPPβ)  to the extracellular space (67,68) and leaves a 99 amino acid long C-
terminal fragment (β-CTF) in the membrane (58). β-CTF becomes subsequently a 
substrate for γ-secretase. Due to the action of the γ-secretase, Aβ is secreted to the 
extracellular space and the APP intracellular domain (AICD) is released into the cytosol 
(figure 5).  
 
Initially it was believed that Aβ production is a pathogenic event. This view was changed 
when it was demonstrated in 1992 that Aβ production was a normal physiological process, 
and that the peptide is detectable in both cerebrospinal fluid and plasma in healthy 
subjects (69-72).  
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Figure 5. Schematic representation of the amyloidogenic processing pathway of APP. The APP 
ectodomain is first shedded by β-secretase to release sAPPβ. The remaining membrane-bound β-
CTF is then further processed by γ-secretase releasing Aβ to the extracellular space and the APP 
intracellular domain (AICD) to the cytosol. 
 
 
 
 
In the non-amyloidogenic pathway (figure 6), the ectodomain of APP is first shedded by α-
secretase resulting in the release of the soluble APP-alpha, sAPPα, to the extracellular 
space, which has neuroprotective and memory enhancing effects (73). This α-cleavage 
takes place between residues 16 and 17 of the Aβ domain thus precluding the formation 
of the Aβ peptide (67,74). After the α-secretase cleavage has taken place, the resultant 83 
amino acid membrane-bound C-terminal fragment or α-C-terminal fragment (α-CTF) (74) 
is further processed by γ-secretase. γ-Secretase cleavage of α-CTF releases the p3 
fragment (75,76) to the extracellular space and AICD (APP intracellular domain) to the 
cytosol (figure 6). 
 
 
 
 
 
 
 
β-secretase
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Figure 6. Schematic representation of the non-amyloidogenic processing pathway of APP. 
Ectodomain shedding of APP by α-secretase occurs within the Aβ domain. The remaining 
membrane-bound α-CTF is then further processed by γ-secretase releasing the p3 peptide to the 
extracellular space and the APP intracellular domain (AICD) to the cytosol. 
 
 
 
γ-Secretase processes APP in its TMD at two major positions, the gamma-site (γ-site), 
which is heterogeneous giving rise to different Aβ species (77) and the also heterogenous 
epsilon-site (ε-site) which releases the 50 or 51 amino acid long residue APP intracellular 
domain or AICD (78-81) (Figure 7). Other γ-secretase substrates as for example Notch 
and CD44 are processed in a similar manner (see section 1.3.3.3.1 and 1.3.3.3.2). 
α-secretase
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sAPPα
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Figure 7. Schematic depiction of APP processing by γ-secretase. Amino acid residues of the APP 
TMD are depicted in red. Heterogeneous cleavages at the γ-site are depicted in green which give 
rise to the different Aβ species shown in green. ε-Site cleavages are depicted in blue, which give 
rise to AICD shown in blue. ζ-Site cleavages are depicted in pink. Big arrows indicate the major 
cleavages. 
 
 
 
Recent evidence suggested that γ-secretase cleaves APP in a step-wise manner with the 
ε-cleavage occurring first, followed by the ζ-cleavage (82,83) (figure 7) and finally the γ-
cleavage (83-85) (figure 8). The major ε-cleavage is at position γ49 (78-81). By 
subsequent cleavage from position γ49 every three amino acids, Aβ40 is produced (figure 
8 A) (84). The minor ε-cleavage is at position γ48 (78-81,86). The cleavage every three 
amino acids from this position results in the production of Aβ42 (figure 8 B). This three 
amino acid cleavage sequence could explain the production of the main Aβ species, Aβ40 
and Aβ42. Thus, Aβ40 and Aβ42 appear to be the result of two product lines. 
…SNK GAIIGLMVGG VV IA TVI V IT L VML KKK…
γ38
γ40
γ42
ε (γ49)
ε (γ48)
ζ (γ46)ζ (γ45)
AICDAβ
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Figure 8. Sequential cleavage of the APP by γ-secretase. Amino acid residues of the APP TMD are 
depicted in red. In panel A, sequential cleavage of APP beginning at γ49 is depicted. In panel B, 
sequential cleavage of APP at γ48 is shown. 
 
 
 
 
 
1.3.2  α- and β-Secretase 
 
Various members of the ADAM (a disintegrin and metalloproteinase) family cleave APP at 
the α-secretase site. ADAMs are type I integral membrane proteins with a catalytic 
domain containing the HEXXH zinc-binding metalloproteinase active site motif (87). 
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ADAMs play an important role in diverse biological processes such as fertilization (88-90) 
neurogenesis (91) heart development (92,93) and the activation of the EGFR growth 
factors and immune regulators such as TNF-α (94). Members of this family, ADAM 17 or 
TACE (Tumour necrosis factor-α convertase), ADAM 10 and ADAM 9 show α-secretase 
activity (95-97). Indeed, knockout and RNAi experiments targeting endogenous TACE, 
ADAM 10 and ADAM 9 have shown that all three enzymes are involved in the α-secretase 
cleavage of APP (97,98).  
 
β-Secretase was identified by different groups as BACE1 (β-site APP cleaving enzyme) 
(99-103). Homozygous BACE1 knockout mice do not produce any Aβ species consistent 
with BACE1 being the enzyme responsible for the β-cleavage of APP (104,105). BACE1 
is a type I membrane protein selectively expressed in neurons. BACE1 contains the 
typical DTGS and DSGT, aspartyl protease active site motifs (101). BACE1 cleaves APP 
at amino acid 1 of the Aβ domain, at amino acid 11 (101,106) and 34 (107). 
 
The physiological role of BACE1 was not clear until recently because BACE1 knockout 
mice showed no major phenotype (105). Recently, however, neuregulin-1 type III has 
been identified as a BACE1 substrate and it has been shown that BACE1 is required for 
myelination in the central and peripheral nervous system and correct bundling of axons 
via processing of neuregulin-1 (108,109). Additional substrates of BACE1 apart from APP, 
are P-selectin glycoprotein ligand 1, (110) and sialyl-transferase ST6gal1 (111). 
 
Soon after the discovery of BACE1, a homologous aspartyl protease was identified, 
BACE2 (112,113). BACE2 process APP at the β-secretase site (114,115) but cleaves with 
more efficiency near the α-secretase cleavage site (115,116). This suggests that BACE2 
acts as an alternative α-secretase lowering the Aβ production. 
 
 
 
1.3.3  γ-Secretase  
 
γ-Secretase is the enzyme responsible for the final cleavage of APP, which occurs within 
its transmembrane domain (TMD). Biochemical and genetic studies have shown that γ-
secretase is a complex composed of four subunits, presenilin (PS), nicastrin (NCT), 
anterior pharynx defective phenotype-1 (APH-1) and presenilin enhancer-2 (PEN-2) 
(figure 9). The four subunits are all integral membrane proteins and necessary and 
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sufficient for γ-secretase activity (117-120) and are in most likely 1:1:1:1 stoichiometry in 
the complex (121). 
 
The calculated molecular weight of these four components together is ~200 kDa. 
Nevertheless, different molecular weights have been reported, from 150 to 2000 kDa 
(118,122-127), pointing to the interesting possibility that the γ-secretase complex could 
exist as a dimer or higher oligomeric forms, or that γ-secretase contains other additional 
components. γ-Secretase catalyses the peptide bond hydrolysis of a substrate in a 
hydrophobic environment of the lipid bilayer and represents an example of an I-Clip 
(Intramembrane-cleaving protease). A low resolution electron microscopy structure has 
suggested that the complex is an almost spherical particle with ~100 Å diameter 
containing a 20-40 Å hydrophilic cavity and 20 Å pores at the top and the bottom of the 
complex, which could represent exit for the products (128). Consistent with a hydrophilic 
cavity, PS1 TMD6 and TMD7 which carry the catalytic aspartates of γ-secretase have 
been shown to be water accessible (129,130). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of the γ-secretase complex and its components. Presenilins 
(PS) 1/2 are depicted in red with the TMD6 and TMD7 highlighted in green. PEN-2 is coloured in 
yellow and Nicastrin is depicted in light blue. APH-1 homologues (APH-1a/b) are depicted in 
maroon. The red arrow points to the endoproteolytic cleavage site in PS1/2. 
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1.3.3.1 Components of the γ-secretase complex 
 
1.3.3.1.1 Presenilin 
 
Membrane topology studies showed that PS is a polytopic 9 transmembrane domain 
protein with the N-terminus and the large loop facing the cytosolic side and the C-terminus 
facing the extracellular side (131-133) (Figure 9). PS is endoproteolyzed within its 
cytoplasmic loop generating N-terminal and C-terminal fragments (134) which remain 
stably associated as heterodimers (122,123,135) (figure 9). This endoproteolysed form is 
part of the γ-secretase complex and is more stable than the full length molecule (136,137).  
 
Two homologues of PS, PS1 and PS2, exist in mammals, which do not exist within the 
same γ-secretase complex (123,138,139). These two molecules show 63% of sequence 
homology and are known as the catalytic subunit of γ-secretase. The first evidence that 
PS is the catalytic subunit of γ-secretase came from studies with PS1 knockout mice 
which showed a strongly reduced γ-secretase activity (140,141). Aspartyl protease 
inhibitors also inhibited the γ-secretase activity (77,142), helping to identify two conserved 
aspartate residues in TMD6 and TMD7. The mutagenesis of these two aspartates 
abrogates the enzyme activity (143-145). Cross-linking studies using γ-secretase 
transition state aspartyl protease inhibitors analogues showed that these compounds 
specifically bind to the PS1 heterodimer (146,147). 
 
Apparently, PS is an unusual aspartyl protease as it does not contain the classical 
aspartyl protease motif, D(T/S)G(T/S) but rather a novel active site motif, the GxGD motif 
around the critical aspartate in TMD7 (148). This GxGD motif has been shown to be 
important for protease activity and for substrate discrimination (148,149) (see chapter 
1.4). 
 
PS endoproteolysis is abrogated when one of the critical aspartates of the active site is 
mutated indicating that PS endoproteolysis might be an autocatalytic mechanism (143). 
Further work strongly suggests that this is indeed the case. Reconstitution of γ-secretase 
activity in yeast which does not contain any γ-secretase has shown that endoproteolysis is 
taking place only when the four γ-secretase components are present (117). 
Endoproteolysis, however, is not strictly required for an active γ-secretase complex. The 
FAD mutation PS1∆Exon9 in which the endoproteolytic cleavage site is deleted and other 
mutations like PS1 M292D and PS1 S141R, PS1 T245I, PS1 R278I, PS1 A434T and PS1 
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L435H result in an uncleaved PS holoprotein but the resulting γ-secretase complex still 
retains activity (150,151). On the other hand, several PS1 G384 mutants undergo 
endoproteolysis but are inactive except for PS1 G384A (148). 
 
PS has also been proposed to have different functions apart from being the catalytic 
subunit of γ-secretase. It has been proposed that uncleaved PS forms passive ER Ca2+ 
ion channels. This would explain the calcium signalling abnormalities that have been 
observed in PS FAD mutations (152,153). Apart from forming Ca2+ ion channels, PS, has 
been shown to affect intracellular trafficking of APP, Notch (154-157), tyrosinase (158) 
tyrosine receptor kinase (141) β- and δ-catenin (159,160), telencephaline and α- and β-
synuclein.  
 
 
1.3.3.1.2 Nicastrin 
 
Nicastrin (NCT) was identified as a γ-secretase complex component by co-
immunoprecipitation studies, which showed that it interacts with PS1 and PS2 (161) 
(figure 9). NCT is a type I membrane glycoprotein with an apparent molecular weight of 
~110 kDa. It has a conserved DYIGS motif, which is important for γ-secretase maturation 
and activity. Mutations in this motif reduce the PS/NCT interaction as well as Aβ 
production (162-164). NCT undergoes complex glycosylation (N- and O-glycosylation) 
through the secretory pathway giving the mature form of NCT, which characterizes a 
mature γ-secretase complex (154,161). Biochemical studies have shown that NCT might 
act as a first docking site for γ-secretase substrates acting as a receptor for membrane-
retained fragments i.e of the shedded substrates, by binding to the free N-terminus (165) 
(see section 1.3.3.4) although these findings have recently been challenged (166). 
 
1.3.3.1.3 PEN-2 
 
PEN-2 (Presenilin enhancer-2) was identified in a genetic screen for PS enhancers in a C. 
elegans strain partially deficient in Sel-12, the C.elegans homologue of PS1 (167) and 
was shown to be a γ-secretase complex component by co-immunoprecipitation and RNAi 
studies (139). PEN-2 is a small 12 kDa hairpin-like membrane protein, which binds to the 
TMD4 of PS1 (168,169) (figure 9). PEN-2 is required for the maturation of the γ-secretase 
complex, in particular for triggering the endoproteolysis of the PS protein (120) and for the 
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stabilization of the NTF and CTF fragments of PS in the complex after endoproteolysis 
has occurred (170,171). The contribution of PEN-2 to the catalytic function of γ-secretase, 
if any, however, remains elusive. 
 
1.3.3.1.4 APH-1 
 
Like PEN-2, APH-1 was identified in a genetic screen carried out in C.elegans for PS 
enhancers as a 20 kDa 7 TMD protein (167,172,173). APH-1 interacts with NCT and with 
PS (174) (figure 9). 
 
In humans two homologues of APH-1 exist, APH-1a and APH-1b, the former occurring in 
two splice variants, APH-1aS and APH-1aL (167,173). All these variants, like PS1 and 
PS2, do not co-exist in the same γ-secretase complex (138,175). Thus, three different 
PS1 and PS2 γ-secretase complexes exist, each differing in the APH-1 homologue 
present, giving a total of six γ-secretase complexes. These complexes, when they contain 
a PS1 or PS2 FAD mutant as catalytic subunit, do not show any difference in the 
pathogenic activity, independently of the APH-1 homologue found in these complexes 
(176). APH-1 has been shown to be important for γ-secretase complex formation acting as 
an assembly scaffold for the complex (177-180). As for PEN-2, the contribution of APH-1 
to the catalytic activity of γ-secretase, if any, has not been elucidated yet. 
 
 
1.3.3.2  γ-Secretase assembly 
 
RNAi and knockout studies have given insight of the γ-secretase complex formation. 
Several studies showed a selective association between APH-1 and immature N-
glycosylated NCT in the absence of PS (163,178,181). Knockdown of NCT and APH-1 by 
RNAi showed a decrease in PS and PEN-2 levels (127,163). On the other hand, a 
knockout of PS does not change the levels of NCT and APH-1 but PEN-2 levels are 
decreased (139). Furthermore, knockdown of PEN-2 expression was accompanied by an 
accumulation of PS holoprotein (170,182).  
 
Taken together this data suggests that the assembly of the γ-secretase complex begins 
with the formation of a NCT/APH-1 complex (177,178). This association serves as a 
scaffold for the assembly of the other two γ-secretase complex components. After the 
INTRODUCTION 
 27
APH-1/NCT scaffold is formed, PS binds forming a ternary complex. The addition of PEN-
2 as the last component triggers the endoproteolysis of PS (120). Biochemical studies 
have shown that the APH-1/NCT scaffold and also the ternary complex containing PS 
occurs on immature NCT, suggesting that and γ-secretase complex formation takes place 
in the ER (180,183). Once the complex is formed is subsequently released from the ER to 
the Golgi compartments, where O-glycosylation of NCT takes place. The mature γ-
secretase complex continues its way through the secretory pathway and reaches its 
functional sites, the plasma membrane and the late compartments of the secretory 
pathway (154,180,184). 
 
Little is known about the control of γ-secretase complex formation. Mainly, γ-secretase 
subunits, which failed to become incorporated into the γ-secretase complex, are rapidly 
degraded by the proteasome pathway (137,185). Rer1 (Retention in endoplasmic 
reticulum 1) is a protein involved in the retrieval of unassembled subunits of multimeric 
complexes in the ER (186). Recent studies have reported that Rer1 can bind to immature 
N-glycosylated NCT (187) or to unassembled PEN-2 (188). These data indicate the 
existence of a quality control system of the γ-secretase assembly to ensure that only fully 
assembled complexes, and not unassembled subunits, leave the ER. 
 
 
1.3.3.3 Substrates of the γ-secretase complex 
 
A large number of γ-secretase substrates have been discovered in the past years (table 
1). These are generally type I transmembrane proteins which the ectodomain has been 
shedded. So far, an unconfirmed exception is the polytopic glutamate receptor subunit 3, 
which does not undergo ectodomain shedding in order to be a γ-secretase substrate 
(189). 
 
All γ-secretase substrates, APP, Notch (1-4) and CD44 (cluster of differentiation 44) that 
were investigated in this thesis follow a similar processing pathway (See figures 10 and 
11). 
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APP APLP1(190) APLP2(190) mNotch1(191) mNotch2(191) 
mNotch3(191) mNotch4(191) CD44(192) Delta(193) Jagged2(193) 
N-
Cadherin(194) 
 
E-Cadherin(194) ErbB4(195) LRP(196) Nectinα (197) 
DCC(198) Syndecan3(199) p75NTR(200) IRE 1α (201) Ephrin B (202) 
IL1R2(203)     
 
Table 1:  γ-Secretase substrates that have been discovered in the past years. 
 
 
1.3.3.3.1 Notch 
 
Notch is a major physiological substrate of γ-secretase. Notch signaling is required for all 
metazoans to specify cell fate and regulate other cell decisions during development and in 
adulthood (204,205). The alteration of this signaling has been associated with different 
cancers and stroke (206). The involvement of γ-secretase in Notch signaling was finally 
shown by genetic studies in C.elegans to be facilitated by Sel-12, the PS1 homologue in 
C.elegans (207). 
Notch is a type I transmembrane receptor protein with a molecular weight of 300 kDa 
(208). Notch exists in four homologues in human, Notch1-4, which are processed in a 
similar way (209). During trafficking through the secretory pathway (Figure 10), Notch is 
cleaved by furin at site 1 (S1). The resultant two fragments remain associated with each 
other forming the mature receptor, reaching the plasma membrane (208,210). At the 
plasma membrane, Notch receptors are activated by type I transmembrane ligands known 
as DSL (Delta, Serrate and Lag 2). Upon ligand binding the ectodomain of the Notch 
receptor is shedded by TACE at the S2 cleavage site. The resultant membrane-anchored 
stub, termed NEXT (Notch extracellular truncated) is then further processed by γ-
secretase at site 3 (S3) within theTMD. This S3 cleavage releases the Notch intracellular 
domain (NICD), which translocates to the nucleus and activates genes important for cell 
fate decisions (204,205). This S3 cleavage resembles the ε-cleavage site in APP 
processing. Furthermore, there is a S4 cleavage site also within the Notch TMD. This S4 
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cleavage is analogous to the γ-cleavage of APP at amino acids 40/42 and releases the 
Notch β peptide (Nβ) to the extracellular space (211).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of Notch processing. S1 cleavage by furin occurs in the Golgi 
network and the mature Notch receptor reaches the plasma membrane, upon ligand activation (not 
shown) the ectodomain is released by ADAM at S2 cleavage. NEXT is then further processed by γ-
secretase at the S3 and S4 cleavage sites releasing Nβ  to the extracellular space and NICD to the 
cytosol. NICD translocates to the nucleus to regulate gene transcription of Notch target genes. 
 
 
1.3.3.3.2 CD44 
 
CD44 is a highly glycosylated type I membrane cell surface adhesion protein and the main 
cell surface receptor for hyaluronan, the principal glycosaminoglycan component of the 
extracellular matrix. CD44 is expressed in most tissues and is implicated in pathological 
and physiological processes such as cancer invasion and metastasis, wound healing, cell 
migration and proliferation (212-214).  
 
The ectodomain of CD44 is first cleaved by ADAM 10, ADAM 17 or membrane-associated 
matrix metalloproteinases (MMPs) MT1-MMP, resulting in a secreted CD44 form (sCD44) 
(215-217). The release of sCD44 regulates the interaction between CD44 and the 
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extracellular matrix during cell migration (218). This ectodomain cleavage is highly 
prevalent in tumours (219). Following ectodomain shedding, the CD44 stub or CD44-CTF 
is cleaved by γ-secretase within the plasma membrane releasing the CD44 intracellular 
domain (CD44-ICD) (192) which translocates to the nucleus and induces expression of 
the CD44 transcript itself (220) and CD44β to the extracellular space (figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic representation of CD44 processing. The CD44 ectodomain is released to the 
extracellular space by ADAMs. The membrane bound CTF is further processed by γ-secretase, 
releasing CD44β to the extracellular space and CD44-ICD, which translocates to the nucleus. 
 
 
 
 
1.3.3.4 Substrate recognition by γ-secretase 
 
As type I membrane proteins, γ-secretase substrates have their N-terminus facing the 
extracellular domain and their C-terminus facing the cytosol and undergo shedding of their 
large ectodomain by α- and β-secretase (221). This shedding event creates a new N-
terminus in the substrate that is subsequently recognized by the ectodomain of NCT thus 
recruiting the substrates into the γ-secretase complex (165). The interaction of the new N-
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terminus of the substrate with the NCT ectodomain depends on the spatial distance and 
steric compatibility of their respective binding sites. Important for binding to the free N-
terminal amino acid from the substrate is residue E333 of the NCT ectodomain (165). This 
interaction allows NCT to recruit the different γ-secretase substrates that have been 
already shedded (165). However, this substrate recognition mechanism has been 
challenged very recently (166). Within the γ-secretase complex, in the PS molecule, a 
second recognition site of the substrate which is different from the active site, the so-
called, “docking site” has been proposed (222,223). This “docking site” of the substrate 
has been recently shown to be three amino acids away from the active site (224). Taken 
together, these findings suggest a two step mechanism for the delivery of the substrate to 
the active site for its processing (figure 12). First, the shedded substrate is recognized by 
NCT and the substrate is subsequently translocated to the docking site. From there, it is 
transferred to the active site for its cleavage. The mechanism by which the substrate is 
transferred from the recognition site to the docking site has, however, not been elucidated 
yet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Model of γ-secretase substrate recognition and cleavage. The shedded substrate is first 
recognized by NCT (blue) (1) and then transferred to the docking site in PS (yellow) (2), from 
where it is moved to the active site (red) (3) for processing (4). Adapted from Shah et al (165). 
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1.3.3.5 γ-Secretase as a therapeutical target 
 
The most straightforward therapeutical approach to attack the progression of AD would be 
to inhibit β- and γ-secretase, the two enzymes responsible for Aβ production. The 
identification and development of β-secretase inhibitors has been difficult as its active site 
is more open and less hydrophobic than in other aspartyl proteases (225). Moreover, 
some β−secretase inhibitors have been reported to be a substrate of P-glycoprotein 
transport resulting in the drug being pump out from the the blood-brain barrier and 
therefore not being able to reach BACE1 in the brain (226-228). In contrast, γ-secretase 
inhibitors have been quickly identified and further developed. The big drawback of the γ-
secretase inhibitors is that indiscriminately block cleavages within the TMDs of γ-
secretase substrates, blocking the formation of ICDs (229). This lack of selectivity gives 
rise to undesirable side effects such as alteration of T cell development (230), increase of 
goblet cell number in the intestine as well as alteration of the intestine tissue morphology 
(231), effects that are due to the block of Notch processing and signalling. It will be 
therefore interesting the development of new γ-secretase inhibitors that selective inhibits 
APP processing but not Notch. Nevertheless, these γ-secretase inhibitors have been 
suggested for the treatment of different tumours because of their ability to inhibit Notch 
signalling as increasing evidence suggests that Notch signalling is frequently dysregulated 
in human neoplasms (232).  
 
Modulation of γ-secretase cleavage might provide a safer way in treating AD than using γ-
secretase transition state analogues. It has been shown that a subset of non-steroidal 
anti-inflammatory drugs (NSAIDs) can modulate γ-secretase activity by reducing the 
production of longer Aβ species (Aβ42) while increasing the production of shorter species 
(Aβ38) in PS1 wt (233). The mechanism by which the modulation of γ-secretase by these 
compounds occurs is still not known, although it is likely that they directly act on the 
protease by a non-competitive mechanism (234-236) that might change the PS1 
conformation (237). Interestingly, ε-cleavage is not affected by this γ-secretase 
modulation. This makes these γ-secretase modulators a more promising alternative to 
complete inhibition of γ-secretase activity in the treatment of AD as they do not interfere 
with Notch or other signalling pathways mediated by ICDs release from γ-secretase 
cleavage (233,234,238). 
 
Another therapeutical approach would be to target the potential modulatory subunits of γ-
secretase. Two proteins, CD147 and TMP21 have been recently suggested as two 
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potential modulatory subunits of γ-secretase (239,240). CD147 is a cell-surface protein 
that stimulates matrix metalloproteinase secretion (241), which has been co-purified with 
γ-secretase. RNAi experiments have shown that ablation of CD147 results in an increase 
of Aβ production, suggesting that CD147 normally down-regulates Aβ production (239). 
Nevertheless, a new study has proposed that CD147 modulates the Aβ production not by 
regulating γ-secretase activity but by the extracellular degradation of Aβ by stimulating 
MMP production (242). TMP21, a trafficking protein, has also been co-purified with γ-
secretase and RNAi experiments have shown that knockdown of TMP21 increases Aβ 
production whereas no changes in AICD production were observed, suggesting that 
TMP21 regulates the γ-cleavage without affecting the ε-cleavage (240). However, further 
research could not fully reproduce the above data of TMP21 (243). TMP21 was not 
present in the mature γ-secretase complex and only a minor increase of Aβ40 was 
observed upon knockdown experiments (243). However, an enhanced of APP maturation, 
APP surface accumulation and a significantly increase in Aβ42 secretion was observed 
(243). Further experiments are needed in order to elucidate the exact role of these two 
proteins within the γ-secretase complex and APP trafficking. 
 
 
 
 
1.4 The GxGD protease family 
 
The GxGD motif found in PS surrounding one of the critical asparates is functionally 
conserved during evolution as it is found in a subset of I-Clips such as the signal peptide 
peptidase (SPP) family, the SPP-like subfamily with SPPL2a, SPPL2b and SPPL3 as 
members (244-247) and the type 4 prepilin peptidase (TFPP) in prokaryotes (248). 
Mutational analysis within the GxGD motif in PS1 which is the prototype of these 
proteases (see section 1.3.3.1.1), has shown the importance of the glycine neighbouring 
the critical aspartate for enzyme activity as a big side chain amino acid abrogates the 
activity of PS1 except when a minor change is introduced as alanine (148) which is a FAD 
mutation changing the ratio Aβ42/Aβ40 (148). The importance of the amino acid in 
position x within the GxGD motif for substrate selection has also been confirmed (149). 
Exchanging the PS1 GLGD motif with the GFGD motif from SPE-4 the most distant PS 
homologue in C.elegans was found to allow APP processing whereas Notch processing 
was heavily impaired suggesting the importance of this amino acid for substrate selection 
INTRODUCTION 
 34 
(149). Taking together, these evidences points to the importance of this functionally 
conserved motif and found a novel aspartyl protease family, the GxGD family (148). 
 
The TFPPs, one of the members of this GxGD family, are eight TMDs integral cytoplasmic 
membrane proteins with two critical aspartate residues located close to TM3 and TM6. 
Mutagenesis of these critical aspartates brings about a loss of activity of the protease 
(249). TFPPs are responsible for the processing of the highly conserved type 4 leader 
peptide present at the N-terminus of the secreted proteins known as type 4 prepilins and 
type 4 prepilin-like proteins (250). The processing has been postulated to be on the 
cytoplasmic side of the membrane and the resultant type 4 pili are polymerised forming 
the pilus, which are surface organelles that are necessary for genetic transfer between 
bacteria pathogens and for virulence (251). 
 
The other family member, SPP/SPPL are polytopic membrane proteins that span the 
membrane nine times that, however, unlike PS, do not undergo endoproteolysis. In 
addition, they do not need other cofactors for their activity (figure 13) (246). Topologically, 
SPP/SPPL are oriented in an opposite direction as PS (246,252) and consistent with this 
topology their substrates are type II transmembrane proteins (253). SPP might be a 
homodimer and the dimerization may be important for the activity of the protease 
(254,255). Mutagenesis of the critical aspartate of the GxGD motif in SPP leads to a loss 
of proteolytic activity (246) in concordance with the mutagenesis of the critical aspartate of 
the GxGD motif in PS and TFPP (143,249). Knockdown of SPP in zebrafish results in cell 
death in the central nervous system (256). Remarkably, expression of an aspartate 
mutant of SPP in zebrafish, reproduce the phenocopy of the knockdown phenotype. 
 
SPP mediates the clearance of the signal peptides of the nascent proteins from the ER 
membrane after their liberation by signal peptidase (257). In addition, it is involved in the 
processing of the hepatitis C virus core protein (258) and the generation of cell surface 
histocompatibility antigen (HLA)-E epitopes in humans (259). Recently two substrates for 
SPPL have been identified, TNFα involved in the transcriptional regulation of IL-12 
(260,261) and Bri protein (262) implicated in British familial dementia (263). Aspartic 
protease transition state analogues inhibit not only γ-secretase but also SPP and SPPL 
and affect the intramembrane cleavage of signal peptides as well as the intramembrane 
proteolysis of TNFα (260,264) thus potentially inhibiting the release of biologically 
important peptides. 
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Figure 13: Schematic comparison of the TFPP, PS and the SPP family. Note the opposite 
topological orientation of PS and SPP. The TMDs that harbour the critical aspartates are 
highlighted in green. 
 
 
 
 
1.5 Aim of the study 
 
A novel class of aspartyl proteases has been discovered which do not carry the typical 
motif for these proteases, (D(T/S)G(T/S)), but rather a novel signature motif, the GxGD 
motif (148). One of these proteases carrying this motif is PS that is one of the key 
proteases in AD as it contributes to the formation of the AD-causing Aβ peptide. This 
novel protease motif has been found in other aspartyl proteases such as the signal 
peptide peptidase family (SPP family) or in the prokaryotic TFPP family, suggesting 
functional conservation of the motif during evolution (148). Previous mutational analysis of 
the glycine neighbouring the critical aspartate in PS1 has shown a loss of activity of the 
protease except when the glycine is substituted to a small side chain amino acid like 
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alanine (148). Moreover, mutational analysis of the amino acid in the position x of PS1 
has shown the importance of this motif for γ-secretase substrate selectivity (149). 
However, the functional role of the GxGD motif is still not known. In particular, is unclear 
why glycines are invariant residues of it. The aim of the study was to investigate the 
functional role of the N-terminal glycine of the GxGD motif. This glycine has been 
proposed to be important based on its sequence conservation among the PS, SPP and 
TFPP families. To investigate the functional role of this glycine a mutational analysis 
approach was carried out, using a mutagenesis approach for PS. 
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2 Materials and methods 
 
2.1 Machines and software 
 
2.1.1 Equipment and instrument. 
 
Shaker (KM2) Edmund Buhler 
Rotator (Rotator shaker genie 2) Scientific Industries 
Thermo-shaker (Thermomixer 5439 compact) Eppendorf 
Magnet stirler (IKAMAG REO) IKA Labortechnik 
Vortex (Vortex Genie 2) Scientific Industries 
Microwave Bosch 
Heatblock Liebisch 
  
Centrifuge for Eppendorf tubes (Biofuge pico) Heraeus, Kendro 
Centrifuge for Eppendorf tubes/4°C (Biofuge pico) Heraeus, Kendro 
Centrifuge/ 4°C/ swing rotor (Megafuge 1.0R) Heraeus, Kendro 
Centrifuge/ 4°C/ swing rotor (Multifuge 3L-R) Heraeus, Kendro 
Centrifuge (J-20XP) 
     Rotors: Type JA10 
Beckman 
Ultracentrifuge (L7-55) 
     Rotors: Ti 50, Ti 70 
Beckman, Sorvall 
Ultracentrifuge (LE-80K) 
     Rotors: Ti 50, Ti 70 
Beckman 
Table Ultracentrifuge (optima ultracentrifuge) Rotor: TLA-55 Beckman 
  
Scale (Analytical +200g-0.0001g) Ohaus 
Scale (Standard 2000g-0.01g) Ohaus 
pH-Meter (Inolab pH Level 1) WTW 
  
Photometer (SmartSpecTM 3000) Bio-Rad 
Disposable cuvette (10x4x45 mm) Sarstedt 
Quarz cuvette (10x10x45 mm) Hellma 
  
Incubator 37°C (Function line) Heraeus 
Incubator 56°C Heraeus 
Freezer -20°C Elektrolux 
Freezer -20°C Liebherr 
Fridge +4°C Elektrolux 
Fridge +4°C Siemens 
Autoclave (Tuttnauer 3850 EL) Systec 
Water deionizing machine (Milli-Q academic) Millipore 
Pipettier (Accu-Jet) Brand 
Pipettes (P2, P20, P200, P1000)  Gilson 
Disposable pipetts (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
Pipette tips (2 µl, 20 µl, 200 µl, 1 ml) Sarstedt 
Disposable tubes (0.2 ml; 0.5 ml; 1.5 ml; 2 ml; 15 ml; 50 ml) Sarstedt 
Centrifuge tubes (1.5 ml) Beckman 
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Centrifuge J-20XP 
(rotor JA10) 
Ultracentrifuges  
L7-55 and LE-80K  
(rotor 50Ti) 
Table 
ultracentrifuge 
(rotor TLA-55) 
Centrifuge for 
Eppendorf tubes, 
Biofuge pico 
xg rpm xg rpm xg rpm xg rpm 
1500 6000 100000 45000 100000 55000 1000 3200 
      3000 6000 
      16000 13000 
Table 2.Velocities for each centrifuge used in this thesis.  
 
 
2.1.2 Recombinant DNA techniques 
 
PCR-machine (Gene Amp PCR system 2400) Perkin Elmer 
37°C incubator (Function line) Heraeus 
37°C shaker (Certomat BS-1) B. Braun Biotech 
International 
Electrophoresis chamber (Model: B1A; Model:B2) Owl Separation 
Systems, Inc 
UV-Lamp (White/Ultraviolet Transilluminator) UVP 
Camera (CCD Video Camera Module) Raiser 
Software (Quicksore plus II) MS Laborgeräte 
Printer (p91) Mitsubishi 
  
 
2.1.3 Cell culture 
 
Clean bench (Hera Safe HS12) Heraeus, Kendro 
CO2-Incubator (Hera cell) Heraeus, Kendro 
Gas burner (Gas profi 1scs) WLD-Tec 
Centrifuge (Megafuge 1.0) Heraeus, Kendro 
Water bath (Typ 1002; Typ 1003) GFL 
Microscope (Wilovert S 10x 4/10/20) Hund 
N2-Tank (Chronos) Messer Griesheim 
Freezer –80°C (HFU 86-450) Heraeus, Kendro 
Cloning ring (8x8 mm) Bellco 
Sterile serological pipettes (2 ml, 5 ml 10 ml, 25 ml) Sarstedt 
Sterile filter pipette tips (2 µl, 20 µl, 200 µl, 1 ml) Sarstedt 
Pasteur pipettes VWR International 
Disposable culture dish (60x15 mm, 100x17 mm, 24 well, 12 well) Nunc 
Microtube (2 ml) PP Sarstedt 
Cell lifter Costar 
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2.1.4 Protein analysis 
 
Electrophoresis chambers: Mini-PROTEAN 3 electrophoresis cell Bio-Rad 
X-Cell Sure LockTM Mini Cell Novex, Invitrogen 
Dual gel caster Hoefer 
Mighty small II for 8x9CM gels Amersham Biosc. 
Transfer chamber: Mini trans-blot transfer cell Bio-Rad 
Power supply (Power Pac 300) Bio-Rad 
Power supply EPS 3501 XC Amersham 
pharmacia biotech 
Power supply EPS 1001 GE health care Bio-
Sciences 
Film developer (Curix 60) Agfa 
Scanner: Epson Perfection 4870 Photo Epson 
  
FluorChemTM 8900 Alpha Innotech 
NIH imager NIH 
 
 
 
 
2.1.5 Sandwich immunoassay 
 
Streptavidin coated 96 well plate MSD 
Multichannel pipette Eppendorf 
Sector Imager 2400 MSD 
  
MSD Workbench software MSD 
Graph Pad Prism 4 software GraphPad software 
 
2.1.6 Mass spectrometry 
 
Sample plate, SS, numbers and circles Applied Biosystems 
Mass spectrometer Voyager-DE STR Applied Biosystems 
  
Voyager control panel 5.10.2 Applied Biosystems 
Data Explorer TM 4.3 Applied Biosystems 
GPMAW 5.02 Lighthouse data 
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2.2 Recombinant DNA techniques 
 
2.2.1 Constructs and vectors 
 
Name of the construct Cloning sites Vector 
 
PS1 wt Eco RI pcDNA 3.1 zeo (+) §1 
PS1 D385A BamHI/XhoI pcDNA 3.1 zeo (+) §2 
PS1 G382A EcoRI/XhoI pcDNA 3.1 zeo (+)  
PS1 G382I EcoRI/XhoI pcDNA 3.1 zeo (+)  
PS1 G382P EcoRI/XhoI pcDNA 3.1 zeo (+)  
PS1 G382W EcoRI/XhoI pcDNA 3.1 zeo (+)  
PS1 G382K EcoRI/XhoI pcDNA 3.1 zeo (+)  
PS1 G382D EcoRI/XhoI pcDNA 3.1 zeo (+)  
H6X-PS1 wt BamHI/XhoI pcDNA 4/His C §3 
H6X-PS1 D385A BamHI/XhoI pcDNA 4/His C §4 
H6X-PS1 G382A EcoRI/XhoI pcDNA 4/His C  
H6X-PS1 G382I EcoRI/XhoI pcDNA 4/His C  
H6X-PS1 G382P EcoRI/XhoI pcDNA 4/His C  
H6X-PS1 G382W EcoRI/XhoI pcDNA 4/His C  
H6X-PS1 G382K EcoRI/XhoI pcDNA 4/His C  
H6X-PS1 G382D EcoRI/XhoI pcDNA 4/His C  
APPsw-6myc ClaI pCS2 (+) §5 
F-NEXT  pcDNA 3.1 hygro (+) §6 
mN2∆E ClaI pCS2 (+) §7* 
mN3∆E ClaI pCS2 (+) §8 
mN4∆E ClaI pCS2 (+) §9 
CD44∆E-Flag Hind/XhoI pSecTag 2/HygroB §10 
 
 
Table 3: cDNA constructs. Overview of the constructs and the vectors as well as the restriction 
enzymes sites, which were used to clone the constructs in the respective vectors. 
§1-§4: These constructs were provided by Dr. Harald Steiner. 
§5: This construct was provided by Dr. Alison Goate (265) 
§6: NEXT construct was provided by Dr. Raphael Kopan (266) and modified by Dr Masayasu 
Okochi (267). 
§7-§9: These constructs were provided by Dr. Raphael Kopan (191). 
§10: This construct was provided by Dr. Sven Lammich (192). 
*This construct additionally carries the M1697L mutation in order to prevent generation of NICD-
sized fragments due to an alternative translation from a methionine within the transmembrane 
domain (191) 
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2.2.2 Primers and template DNA 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Forward (F) and reverse (R) primer pairs used for the construction of the different PS1 
G382 mutants are shown. 
 
 
2.2.3 PCR reaction mixtures 
 
 
 
 
 
 
 
 
 
 
 
The PCR reaction mixture used for the construction of the PS1 G382 mutants is shown.  
 
 
2.2.4 PCR programs 
 
 
 
 
 
 
 
 
The PCR program used for constructing the PS1 G382 mutants mutants is shown. 
 
94°C 4 min
94°C 1 min
55°C 1 min 15 cycles
72°C 2 min
72°C 10 min
4°C ∞
Construct Primer Pairs cDNA template
PS1 wt F: 5'-CCG-AAT-TCA-AGA-AAG-AAC-CTC-AA-3' PS1 wt
R: 5'-CGC-CTC-GAG-GCA-AAT-ATG-CTA-GAT-ATA-3'
PS1 G382A F: 5'-AGG-GGA-GTA-AAA-CTT-GCA-TTG-GGA-GAT-TTC-ATT-TTC-3' PS1 wt
R: 5'-AAT-GAA-ATC-TCC-CAA-TGC-AAG-TTT-TAC-TCC-CCT-TTC-3'
PS1 G382I F: 5'-AGG-GGA-GTA-AAA-CTT-ATA-TTG-GGA-GAT-TTC-ATT-TTC-3' PS1 wt
R: 5'- AAT-GAA-ATC-TCC-CAA-TAT-AAG-TTT-TAC-TCC-CCT-TTC-3'
PS1 G382P F: 5'-AGG--GGA-GTA-AAA-CTT-CCA-TTG-GGA-GAT-TTC-ATT-TTC-3' PS1 wt
R: 5'-AAT-GAA-ATC-TCC-CAA-TGG-AAG-TTT-TAC-TCC-CCT-TTC-3'
PS1 G382W F: 5'-AGG-GGA-GTA-AAA-CTT-TGG-TTG-GGA-GAT-TTC-ATT-TTC-3' PS1 wt
R: 5'-AAT-GAA-ATC-TCC-CAA-CCA-AAG-TTT-TAC-TCC-CCT-TTC-3'
PS1 G382K F: 5'-AGG-GGA-GTA-AAA-CTT-AAA-TTG-GGA-GAT-TTC-ATT-TTC-3' PS1 wt
R: 5'-AAT-GAA-ATC-TCC-CAA-TTT-AAG-TTT-TAC-TCC-CCT-TTC-3'
PS1 G382D F: 5'-AGG-GGA-GTA-AAA-CTT-GAC-TTG-GGA-GAT-TTC-ATT-TTC-3' PS1 wt
R: 5'-AAT-GAA-ATC-TCC-CAA-GTC-AAG-TTT-TAC-TCC-CCT-TTC-3'
cDNA template (200 ng) 1 µl
Forward Primer (1µg/µl) 1 µl
Reverse Primer (1µg/µl) 1 µl
10xPCR reaction buffer complete (Peq Lab) 10 µl
dNTPs (10 mM, Roche) 2 µl
Pwo DNA polymerase (1U/µl, Peq Lab) 2.5 µl
dH2O 82.5 µl
Final volume 100 µl
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2.2.5 Two-step PCR 
 
Two-step PCR was performed to introduce mutations in the construct. The first PCR was 
performed using the indicated primer pairs (see section 2.2.2). The PCR products were 
isolated and purified as described (see section 2.2.6.3). Aliquots of purified PCR products 
were mixed (1:1) and this mixture was used as template for the second PCR. The second 
PCR was performed using the outer primer pairs. 
 
 
 
2.2.6 Isolation and purification of PCR products 
 
2.2.6.1 Materials 
 
 TBE-buffer: 
 9 mM Tris, 2 mM EDTA in dH2O 
 6x DNA-loading buffer: 
 30% Glycerol, 0.25% bromophenolblue and 0.25% xylenecyanol FF in dH2O 
 Agarose (Amersham Biosciences) 
 1 kb DNA ladder (Gibco Invitrogen Corporation) 
 Nucleo Spin Extraction Kit (Macherey-Nagel) 
 Ethidiumbromide (Sigma) 
 
 
2.2.6.2 Agarose gel electrophoresis 
 
After the PCR, DNA loading buffer was added to the PCR reaction mixture to a one-fold 
final concentration. PCR products were loaded on a 1% agarose gel in TBE buffer 
containing 0.2 µg/µl ethidiumbromide and separated by electrophoresis at 150 volts. 1 kb 
DNA ladder was loaded in parallel to the PCR products as size standard (see section 
2.2.6.1). 
 
2.2.6.3 Isolation and purification of PCR products from agarose gels 
 
The right-sized PCR products, confirmed under the UV-lamp, were cut out from the 
agarose gel and purified from the agarose gel using the Nucleo Spin Extraction Kit 
following the manufacturer’s instructions (see section 2.2.6.1). The purified DNA 
fragments were used as template for the second PCR or treated with restriction enzymes 
(see section 2.2.7.1) to allow their subcloning. 
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2.2.7 Enzymatic modification of cDNA fragments 
 
2.2.7.1 Enzymes and vectors 
 
 Restriction Enzymes: 
 EcoRI (10U/µl) (MBI Fermentas) 
 XhoI (10U/µl) (MBI Fermentas) 
 Alkaline phosphatase: 
 Shrimp alkaline phosphatase (SAP;1U/µl) (Roche) 
 Ligase: 
 T4 DNA ligase (5U/µl) (Roche) 
 Vectors: 
 pcDNA 3.1/zeo (+) (Invitrogen) 
 pcDNA 4/HisC (Invitrogen) 
 
 
2.2.7.2 Restriction enzyme treatment 
 
The purified DNA fragments were digested with 10U of the corresponding restriction 
enzymes and the appropriate reaction buffer supplied by the manufacturer. The mixture 
was adjusted to a final volume of 30 µl with dH2O and incubated at 37°C overnight. Three 
µg of the appropriate vector were also digested with the corresponding restriction 
enzymes (see section 2.2.7.1) for 2 h at 37°C. After the digestion reaction cDNA 
fragments were isolated by agarose electrophoresis (see section 2.2.6.2) and purified with 
Nucleo Spin Extraction Kit (see section 2.2.6.3). 
 
2.2.7.3 Alkaline phosphatase treatment 
 
Linearized vectors were treated with SAP (see section 2.2.7.1) to dephosphorylate DNA 
ends in order to avoid self-ligation. 1U of SAP per 10-15 µg of vector was used with 
reaction buffer from the manufacturer. The mixture was incubated at 37°C for 1 h followed 
by incubation at 65°C for inactivation of the enzyme for 20 min. 
 
2.2.7.4 Ligation of cDNA fragments 
 
Ligation of cDNA fragments to the linearized vectors was performed using 2U of T4 ligase 
(see section 2.2.7.1) and a ratio of 1:6 (Vector: cDNA fragments) with the reaction buffer 
from the manufacturer in a final volume of 20 µl. The mixture was incubated for 1h at room 
temperature. The ligation mixture was then used for E.coli transformation (see section 
2.2.8). 
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2.2.8 Transformation of E.coli 
 
2.2.8.1 Materials 
 
 LB medium (Low salt Luria-Bertani Medium): 
 1% Tryptone; 0.5% yeast extract; 0.5% NaCl in dH2O (adjust to pH 7.0) autoclaved 
at 120°C/ 1.2 bar for 20 min. 
Transformation buffer: 
50 mM CaCl2; 15 % glycerol; 10 mM PIPES buffer, pH 6.6, autoclaved and stored  
at 4°C. 
LB agarose plates with ampicillin: 
LB medium; 1.5% agarose with 100 µg/ml of ampicillin, autoclaved at 120°C/ 1 bar 
for 20 min. 
Competent E.coli strain: 
DH5α 
 
2.2.8.2 Preparation of competent cells 
 
DH5α cells were cultured overnight in LB medium (see section 2.2.8.1). Cells were diluted 
with fresh LB medium and adjusted to OD A600=0.05. 5 ml were inoculated to 400 ml LB 
medium and grown for 2-3 hours to an OD A600 of 0.2. Cells were then chilled on ice for 10 
min and centrifuged at 1500xg for 10 min at 4°C. The cells were resuspended in 200 ml of 
transformation buffer  (see section 2.2.8.1), chilled on ice for 20 min and centrifuged again 
at 1500xg for 10 min at 4°C. Cells were then resuspended in 20 ml of transformation 
buffer. Aliquots of the suspension were frozen in liquid N2 and stored at –80°C until further 
use. 
 
2.2.8.3 Transformation of E.coli 
 
75-100 µl of competent cells were added to the ligation mixture (see section 2.2.8.1). The 
mixture was then incubated for 20 min on ice followed by a heat-shock treatment of 42°C 
for 30 seconds and further incubation for 2 min on ice. 300 µl of fresh LB medium was 
added to the ligation mixture and was incubated at 37°C for 45 min shaking. The mixture 
was then plated onto LB-agarose plates containing 100 µg/ml of ampicillin (see section 
2.2.8.1) and incubated overnight at 37°C. 
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2.2.9 Preparation of plasmid DNA from E.coli 
 
2.2.9.1 Materials 
 
 LB medium  
(See section 2.2.8.1) 
 NucleoSpin plasmid (Macherey-Nagel) 
 Nucleobond AX 500 kits (Macherey-Nagel) 
 TE buffer: 
 10 mM Tris pH 7.6; 1 mM EDTA pH 8.0 in dH2O 
 
2.2.9.2 Small-scale plasmid DNA preparation (mini-prep) 
 
E.coli colonies from the LB-agarose plates were picked and inoculated into 2 ml of fresh 
LB medium containing 100 µg/ml of ampicillin and incubated overnight at 37°C with 
shaking. 1.5 ml of the culture was then used for a small scale plasmid DNA isolation using 
the NucleoSpin plasmid kit following the manufacturer’s instruction (see section 2.2.9.1). 
The plasmid DNA obtained was resuspended in 40 µl of TE buffer (see section 2.2.9.1). 
 
 
2.2.9.3 Mini-prep analysis 
 
5 µl of miniprep DNA were digested with the corresponding restriction enzymes (see 
section 2.2.7.1) in order to identify positive E.coli clones carrying the correct plasmid. After 
the restriction digest, the DNA fragments were separated in an agarose gel (see section 
2.2.6.2). The positive clone containing the correct size of insert was selected and used for 
large-scale DNA preparation (see section 2.2.9.4). 
 
2.2.9.4 Large scale plasmid DNA preparation (maxi-prep) 
 
10 µl of the overnight culture from the positive clone identified by miniprep analysis was 
inoculated to 200 ml of LB medium containing 100 µg/ml of ampicillin and incubated 
overnight with shaking at 37°C. Plasmid DNA was isolated using the Nucleobond AX 500 
kit following the manufacturer’s instructions (see section 2.2.9.1). Purified plasmid DNA 
was resuspended in 200-500 µl of TE buffer (see section 2.2.9.1). DNA concentration was 
measured by photometry at OD A260. 
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2.2.9.5 DNA sequencing 
 
All cDNA constructs were sequence by GATC Biotech AG (Konstanz, Germany) to verify 
successful site-directed mutagenesis and to rule out second-site mutations. 
 
 
2.3 Cell culture and cell lines 
 
2.3.1 Materials 
 
 Dulbecco’s modified Eagle’s medium (DMEM) high glucose (Gibco Invitrogen 
corporation) 
Fetal bovine serum (FBS) (PAA) 
L-glutamine (Gibco Invitrogen corporation) 
Penicillin/Streptomycine (Pen/Strep) (Gibco Invitrogen corporation) 
Geniticin (G418) (Gibco Invitrogen corporation) 
Zeocin (Zeo) (Gibco Invitrogen corporation) 
Trypsin-EDTA (Gibco Invitrogen corporation) 
PBS: 
140 mM NaCl; 10 mM Na2HPO4 2H2O; 1.75 mM KH2PO4; 2.7 mM KCl autoclaved  
and stored at room temperature 
R,S Flurbiprofen (Calbiochem; Cat No: 344079): 250 mM stock solution dissolved 
in DMSO and stored at –20°C 
Sulindac sulfide (Sigma; Cat No: S3131): 250 mM stock solution dissolved in 
DMSO and stored at –20°C 
Fenofibrate (Sigma; Cat No: F6020): 250 mM stock solution dissolved in DMSO 
and stored at –20°C 
S Naproxen (Sigma; Cat No: N8280): 250 mM stock solution dissolved in DMSO 
and stored at –20°C 
DMSO (Merck) 
Lactacystin (Calbiochem): 10 mM stock solution dissolved in DMSO and stored at 
–20°C 
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2.3.2 Cell lines and culture medium 
 
Cell lines Antibiotics 
PS1/PS2 -/- MEF Pen/Strep/G418 
HEK293 Pen/Strep 
HEK293/sw Pen/Strep/G418 
HEK293/sw/H6X-PS1wt Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 D385A Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 G382A Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 G382I Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 G382P Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 G382W Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 G382K Pen/Strep/G418/Zeo 
HEK293/sw/H6X-PS1 G382D Pen/Strep/G418/Zeo 
  
2.3.3 Cell culture 
 
Mouse embryonic fibroblasts (MEF) derived from PS1/PS2 double knock out mice (268) 
were cultured in DMEM Glutamax supplemented with 10% FBS, 1% L-glutamine, 1% of 
Pen/Strep and 200 µg/ml of G418 under 5% CO2 and at 37°C (see section 2.3.1). For 
inoculation, cells were washed with PBS and trypsinized for 5 min. An appropiate amount 
of cells was transferred to a new plate with fresh medium. Human embryonic kidney cells 
(HEK) 293 cells stably expressing human APP carrying the Swedish mutation (HEK/sw) 
(36) were cultured and spread as before. HEK/sw cells stably expressing the H6X-PS1 
constructs (see section 2.2.1) were cultured in DMEM Glutamax supplemented with 10% 
FBS, 1% L-glutamine, 1% Pen/Strep, 200 µg/ml of G418 and 0.2 µg/ml of zeocin and 
spread as before (see section 2.3.1). Untransfected HEK cells were cultured in DMEM 
Glutamax supplemented with 10% FBS, 1% L-glutamine and 1% Pen/Strep under 5% 
CO2 at 37°C (see section 2.3.1).  
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2.3.4 Transfection of mammalian cells 
 
2.3.4.1 Materials 
 
 OptiMEM medium (Gibco Invitrogen corporation) 
 Lipofectamine 2000 transfection reagent (Invitrogen) 
 
2.3.4.2 Transfection mixture 
 
culture dishes volume of culture medium total cDNA Lipofectamine 2000 
10 cm 10 ml 16 µg 40 µl 
 
2.3.4.3  Transient co-transfection 
 
One tenth of PS1/PS2 -/- MEF cells from a confluent 10 cm dish were spread into a 10 cm 
dish containing 10 ml of culture medium without antibiotics. On the next day, cells were 
transiently co-transfected with the respective combinations of two cDNAs (encoding 
substrate and protease) using lipofectamine 2000 (see section 2.3.4.1). In total, 16 µg of 
cDNAs (8 µg/cDNA) and 40 µl of lipofectamine 2000 per dish were used. First, cDNAs 
and lipofectamine 2000 were mixed with 1 ml of OptiMEM (see section 2.3.4.1) and 
incubated for 5 min at room temperature. Both solutions were mixed, incubated for 20 min 
at room temperature and then gently added onto the cells. 24 hours after transfection, the 
medium was replaced with 4.5 ml of fresh OptiMEM (see section 2.3.4.1) and conditioned 
for another 16 hours. 
 
2.3.4.4 Stable transfection 
 
To establish stable cell lines, HEK293 or HEK/sw cells were transfected with the 
corresponding cDNA as described before (see section 2.3.4.3). One day after 
transfection, cells were split 1:10 to 1:1000. Two days after transfection, zeocin was 
added at final concentration of 0.2 mg/ml to select the resistant cells for 2-3 weeks. Single 
cell clones were isolated using cloning-cylinders, transferred to a 24 well plate and 
cultured. Single cells clones were checked for expression levels of the transfected cDNA 
by immunoblotting and a representative single cell clone with a robust expression was 
selected as working clone. 
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2.3.4.5 Drug treatment of cells  
 
For proteasome inhibition experiments, a 10 mM stock of lactacystin (269) was prepared 
in DMSO. The drug was then diluted to the desired final concentration for the treatment of 
cells in a 10 cm dish in 4.5 ml of DMEM GlutaMAX media containing FBS, L-glutamine 
and Pen/Strep and the drug containing medium was gently added to the cells. For non-
steroidal anti-inflammatory drug (NSAID) treatment of cells in a 10 cm dish, a 250 mM 
stock solution of each drug was prepared in DMSO. The drug was diluted to the desired 
final concentration in 4.5 ml of DMEM GlutaMAX media containing FBS. Medium was 
gently added to the cells and incubated for 24 hours. Medium was removed and fresh 
media containing the desired NSAID concentration was again added and incubated for 
another 24 hours. For fenofibrate treatment, a lipid regulating drug (270) cells were 
incubated for 8 hours with the desired drug concentration as before. 
 
2.4 Antibodies 
 
2.4.1 Monoclonal antibodies 
Antibody Epitope Reference/supplier IP Blot SIA 
PS1N PS1 
N-terminus 
(Capell et al., 
1997) 
 1:5000  
6E10 Aβ 
aa 1-16 
Signet 
Laboratories 
 1:10000  
M2 
 
FLAG 
peptide 
Sigma  1:1000  
9E10 C-Myc 
peptide 
Santa Cruz 
Biotechnology 
 1:2000  
Xpress Xpress 
peptide 
Invitrogen 1:150   
2D8-biotin Aβ 
aa 1-16 
(Shirotani et al., 
2007) 
  1:1000 
Aβ38-
Ruthenium tag 
Aβ 
 
MSD   1:1000 
Aβ40-
Ruthenium tag 
Aβ 
aa 34-40 
(Brockhaus et al., 
1998) Roche 
  1:1000 
Aβ42-
Ruthenium tag 
Aβ 
aa 36-42 
(Brockhaus et al., 
1998) Roche 
  1:1000 
4G8 Aβ 
aa 17-24 
Covance 5 µl 4G8/15 µl 
beads (MS) 
  
IP: Immunoprecipitation; SIA: Sandwich immunoassay; MS: Mass spectrometry 
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2.4.2 Polyclonal antibodies 
Antibody Epitope Reference/supplier IP Blot 
3027 PS1 
aa 263-407 
(Walter et al., 
1997) 
 1:1000 
N1660 NCT 
aa 693-709 
Sigma  1:5000 
6687 APP 
last 20 aa 
(Steiner et al., 
2000) 
 1:1000 
3552 Aβ 
aa 1-40 
(Yamasaki et al., 
2006) 
1:300  
Cleaved Notch1 NICD 
aa V1744 
Cell signalling 
Technology 
 1:1000 
β-catenin β-catenin  
aa 571-781 
BD Transduction 
laboratories 
 1:8000 
 
 
 
 
2.4.3 Secondary antibodies 
Antibody Epitope Reference/supplier Blot 
Anti-rabbit-HRP Rabbit IgG Promega 1:10000 
Anti-mouse-HRP Mouse IgG Promega 1:10000 
Anti-mouse-AP Mouse IgG Promega 1:5000 
 
 
 
2.5 Protein analysis 
 
2.5.1 Total cell lysate 
 
2.5.1.1 Materials 
 
 PBS: 
 See section 2.3.1 
 STEN-lysis buffer: 
 50 mM Tris pH 7.6; 150 mM NaCl; 2 mM EDTA; 1% NP-40 in dH2O 
 BSA solution: 
 2 mg/ml Albumin from bovine serum in dH2O (Sigma) 
 Complete Mini protease inhibitor cocktail tablets (Roche) 
 BIO-RAD protein assay (BIO-RAD) 
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2.5.1.2 Cell lysate preparation 
 
Confluent cells were washed with PBS buffer (see section 2.3.1), collected and pelleted in 
Eppendorf tubes by centrifugation for 5 min at 1000xg at 4°C. Cells from a 10 cm dish 
were lysed with 500 µl of STEN-lysis buffer (see section 2.5.1.1) with 1x complete mini 
protease inhibitor cocktail (see section 2.5.1.1) and incubated for 20 min on ice. The cell 
lysate was then ultracentrifuged for 20 min at 100000xg at 4°C, the supernatant was 
transferred to a new Eppendorf tube, and the protein concentration of the cell lysate was 
measured by the Bradford protein assay from BIO-RAD (see section 2.5.1.3). 
 
 
2.5.1.3 Protein quantitation 
 
Total cell lysate protein concentration was measured by the Bradford assay. 1 µl of total 
cell lysate was mixed with 1 ml of BIO-RAD protein assay solution (see section 2.5.1.1), 
diluted with dH2O (1:5), incubated for 5 min at room temperature and the OD A595  was 
measured with a
 
photometer, in parallel, 2 µl of 2 mg/ml BSA were measured as standard. 
 
 
2.5.2 Membrane lysate 
 
2.5.2.1 Materials 
 
 PBS: 
 See section 2.3.1 
 Hypotonic buffer: 
 10 mM MOPS, 10 mM KCl in dH2O, pH 7.0 
 Co-IP buffer: 
 150 mM Na-citrate pH 6.4 in dH2O. 
 10% CHAPSO: 
 10% CHAPSO in dH2O 
 BSA solution: 
 See section 2.5.1.1 
 Complete Mini protease inhibitor cocktail tablets (Roche) 
 Needle 23G (B-Braun) 
 
2.5.2.2 Preparation and solubilization of membrane 
 
The cell pellet of a 10 cm dish was resuspended in 500 µl of hypotonic buffer containing 
protease inhibitor cocktail (see section 2.5.2.1) and incubated on ice for 20 min. The cell 
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suspension was passed 10 times through a syringe equipped with a 23G needle and 
centrifuged 15 min at 1000xg at 4°C to pellet nuclei and unbroken cells. The resultant post 
nuclear supernatant was transferred to a new Eppendorf tube and centrifuged for 45 min 
at 16000xg at 4°C to pellet the membranes. The membrane fraction was then solubilized 
with 1% CHAPSO in Co-IP buffer containing protease inhibitor cocktail (see section 
2.5.2.1) for 20 min at 4°C and ultracentrifuged for 30 min at 100000xg at 4°C to pellet the 
unsolubilized membranes. The supernatant was transferred to a fresh Eppendorf tube and 
the protein concentration was measured by the Bradford assay as described (see section 
2.5.1.3). 
 
 
2.5.3 Immunoprecipitation 
 
2.5.3.1 Materials 
 
 PBS: 
 See section 2.3.1 
 Protein A Sepharose (PAS) 
 1 g PAS / 10 ml STEN; 2 mg/ml BSA 
 STEN-NaCl: 
 50 mM Tris pH 7.6; 500 mM NaCl; 2 mM EDTA pH 8.0; 0.2% NP-40 in dH2O 
 STEN-SDS: 
 50 mM Tris pH 7.6; 150 mM NaCl; 2 mM EDTA pH 8.0; 0.1% SDS; 0.2% NP-40 in 
dH2O 
 STEN: 
 50 mM Tris pH 7.6; 150 mM NaCl; 2 mM EDTA pH 8.0; 0.2% NP-40 in dH2O 
 TBS: 
 10 mM Tris pH 7.4; 150 mM NaCl 
 Anti-FLAG M2 agarose (Sigma) 
 Anti-c-myc agarose (Sigma) 
 
2.5.3.2 Immunoprecipitation from total cell lysate 
 
Immunoprecipitations from total cell lysate were performed to analyse CD44-ICD 
formation. Anti c-myc agarose were washed three times with PBS (see section 2.5.3.1) 
and 25 µl of those were added to the total cell lysate (see section 2.5.1) and were 
incubated overnight at 4°C with shaking. Beads were collected by centrifugation at 3000xg 
for 5 min at 4°C and washed three times with 1 ml of PBS. After the washes, the 
supernatant was carefully removed and 20 µl of SDS-SB was added to the beads (see 
section 2.5.6.1). 
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2.5.3.3 Immunoprecipitation from conditioned media. 
 
Secreted Aβ, Nβ and CD44β  were analysed by combined immunoprecipitation/ 
immunoblotting from conditioned media. The conditioned media (optiMEM) (see section 
2.3.4.1) from PS1/PS2 -/- MEF cells transiently co-transfected with the corresponding 
cDNAs, were collected into a Falcon tube and centrifuged at 3000xg for 5 min to pellet 
cells present in the media. For Aβ, 4 ml of media were precleareded with 20 µl of PAS 
(see section 2.5.3.1) for 30 min at 4°C. After centrifugation at 3000xg for 5 min at 4°C, the 
precleareded conditioned media was transferred to a new Falcon tube and 25 µl of PAS 
and anti-Aβ antibody 3552 (see section 2.4.2) were added and incubated overnight at 4°C 
with shaking. The immunoprecipitates were washed with 1 ml of STEN-NaCl, STEN-SDS 
and STEN (see section 2.5.3.1) and 20 µl of urea-SDS-SB was added to the beads (see 
section 2.5.6.1). 
 
For Nβ and CD44β, 4 ml of the conditioned media (optiMEM) was directly subjected to 
immunoprecipitation with 25 µl of FLAG-M2 agarose (see section 2.5.3.1) previously 
washed with PBS. Nβ was immunoprecipitated overnight at 4°C whereas CD44β was 
immunoprecipitated at 4°C for 4 hours. In both cases, after the corresponding times, 
beads were washed 3 times with 1 ml of TBS (see section 2.5.3.1). After the last wash, 
the supernatant was carefully removed and 20 µl of urea-SDS-SB was added to the 
beads. To analyse Aβ from HEK293/sw cells stably expressing the different PS1 
constructs (see section 2.5.3.1), DMEM + GlutaMax media were conditioned for 16 hours. 
Secreted Aβ species were immunoprecipitated as described above, eluted with urea-SDS-
SB or Tris-bicine-urea-SB (see section 2.5.6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 54 
2.5.4 In vitro γ-secretase assay 
 
2.5.4.1 Materials 
 
 PBS: 
 See section 2.3.1 
 Hypotonic buffer: 
 See section 2.5.2.1 
 Na-citrate buffer: 
 150 mM Na-citrate pH 6.4 in dH2O 
 Washing buffer: 
 0.5% CHAPSO; 150 mM Na-citrate pH 6.4 in dH2O 
 10% CHAPSO: 
 see section 2.5.2.1 
 Purified recombinant C100-His6 (271)  
 Phosphatidylcholine (Sigma) 
 DTT (Biomol) 
 BSA: 
 See section 2.5.1.1 
 Complete Mini protease inhibitor cocktail tablets (Roche) 
 Reaction mix: 
 150 mM Na-citrate, pH 6.4; 0.25% CHAPSO; 0.5 mg/ml phosphatidylcholine; 
 10 mM DTT; 0.1 mg/ml BSA and complete mini protease inhibitor cocktail. 
 
2.5.4.2 Membrane preparation and in vitro γ-secretase assay 
 
Stable HEK293/sw cells stably expressing the H6X-PS1 constructs (see section 2.2.1) 
were used to analyse de novo AICD generation. Cells from a confluent 10 cm dish were 
washed with PBS, recollected into an Eppendorf tube, and centrifuged for 5 min at 1000xg 
at 4°C to pellet the cells. The pellet was then resuspended in 500 µl of hypotonic buffer 
(see section 2.5.2.1) containing 1x complete mini protease inhibitor cocktail (see section 
2.5.4.1) and incubated on ice for 20 min. Cell suspension was then passed 10 times 
through a syringe equipped with a 23G needle followed by centrifugation for 15 min at 
1000xg at 4°C. The supernatant was transferred into a new Eppendorf tube and further 
centrifuged for 45 min at 16000xg at 4°C to collect the membrane fraction. The membrane 
pellet was solubilised with Na-citrate buffer containing 1% CHAPSO (see section 2.5.4.1) 
and 1x complete mini protease inhibitor cocktail and incubated for 20 min on ice. After 30 
min centrifugation at 100000xg at 4°C, protein concentrations of the samples were 
determined by the Bradford assay (see section 2.5.3.1). The volume of membrane 
suspensions of the different cell lines to be used for the in vitro γ-secretase assay was 
adjusted depending on the protein concentration. Samples were then precleared with 
bridge antibody coupled to PAS (see section 2.5.3.2) for 30 min at 4°C to avoid unspecific 
binding to the beads. The precleared lysate was subjected to immunoprecipitation with 
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Xpress antibody (see section 2.4.1) for 2 hours at 4°C with shaking. After 3 washes with 
washing buffer (see section 2.5.4.1) containing complete mini protease inhibitor cocktail, 
20 µl of reaction mix (see section 2.5.4.1) was added to the beads and incubated with 1 µl 
of C100-His6 (see section 2.5.4.1) overnight at 37°C to allow AICD generation. 
 
 
2.5.5 Sample preparation for SDS-PAGE 
 
2.5.5.1 Materials 
 
Urea-SDS-sample buffer (SB): 
 62.5 mM Tris pH 6.8; 2% SDS; 10% glycerol; 2.5% β-mercaptoethanol; 2 M urea; 
 bromophenolblue in dH2O 
 SB for modified Tris-bicine-urea gel: 
 0.72 M Bis-Tris; 0.32 M bicine; 2% SDS; 5% β-mercaptoethanol; 30% sucrose; 
 bromophenolblue in dH2O 
 Prestained protein standard; See Blue Plus 2 (Invitrogen) 
 
2.5.5.2 Sample preparation 
 
To detect NCT; PS1NTF, PS1CTF; APPCTFs; APPsw-6myc; AICD; F-NEXT; NICDs; mN2∆E; 
mN3∆E; mN4∆E; CD44CTFs; CD44-ICD; total cell lysates were analysed by 
immunoblotting. 25-50 µg of proteins were denaturated by adding urea-SDS-SB (see 
section 2.5.6.1) and boiling for 10 min at 65°C before applying them to the gel. Samples 
were separated by SDS-PAGE (section 2.6). 12% Tris-glycine SDS-PAGE (see section 
2.6.1) was used to separate CD44CTFs and CD44-ICD; 10 % Tris-glycine-urea SDS-PAGE 
was used to separate NCT, PS1NTF, PS1CTF, APPsw-6myc (CTFs and AICD) (see section 
2.6.1); 7% Tris-glycine SDS-PAGE was used to separate NICDs, F-NEXT, mN2∆E, 
mN3∆E and mN4∆E (see section 2.6.1). To detect AICD and Aβ derived from in vitro γ-
secretase assays, urea-SDS-SB was added to the reaction mixture and boiled for 10 min 
at 95°C. AICD and Aβ were separated in a 10%-20% Tris-tricine gel (see section 2.6.2). 
Immunoprecipitated Aβ from stably transfected HEK/sw cells and Aβ, Nβ, CD44β from 
transiently transfected MEF cells on PAS or anti-FLAG M2 agarose, were released from 
the beads and denaturated by adding urea-SDS-SB or SB for modified Tris-bicine-urea 
gel (see section 2.5.6.1) and boiling for 10 min at 95°C. Total Aβ, Nβ and CD44β, were 
separated in a 10%-20% Tris-tricine gel. A modified Tris-bicine-urea gel was used to 
separate Aβ38/Aβ40/Aβ42 species. To detect APPCTFs co-immunoprecipitated with γ-
secretase complex, immunoprecipitates were boiled for 10 min at 65°C in urea-SDS-SB. 
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APPCTFs were separated on a 10-20% Tris-tricine gel and γ-secretase complex 
components were separated on a 10% Tris-glycine-urea gel.  
 
 
2.6 SDS-Polyacrylamide gel electrophoresis (PAGE) 
 
2.6.1 Tris-glycine gels 
 
2.6.1.1 Materials 
 
 Lower Tris (4x): 
 1.5 M Tris pH 8.8; 0.4% SDS; in dH2O 
 Upper Tris (4x): 
 0.5 M Tris pH 6.8; 0.4% SDS in dH2O 
 Acrylamide (SERVA): 
 40% (w/v) acrylamide/bis-acrylamide 37.5:1 in dH2O 
 8 M urea solution: 
 8 M urea in dH20 
 APS: 
 10% (w/v) ammonium persulfat in dH2O 
 Tris-glycine gel running buffer: 
 25 mM Tris; 200 mM glycine; 0.1% SDS in dH2O 
 N,N,N’,N’-tretramethylethylethylendiamine (TEMED) (Merck) 
2.6.1.2 Gel preparation 
 
For one thick (1.5mm) mini gel: 
 
 
7% 
separating 
gel 
12% 
separating 
gel 
stacking 
gel 
10% urea 
separating 
gel 
urea 
stacking 
gel 
8 M urea - - - 2.6 ml 2.5 ml 
40% acrylamide 1.31 ml 2.25 ml 487.5 µl 1.875 ml 487.5 µl 
4x lower Tris 1.875 ml 1.875 ml - 1.875 ml - 
4x upper Tris - - 1.25 ml - 1.25 ml 
dH2O 4.315 ml 3.37 ml 3.4 ml 1.125 ml 0.91 ml 
APS 15 µl 15 µl 15 µl 15 µl 15 µl 
TEMED 15 µl 15 µl 15 µl 15 µl 15 µl 
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2.6.1.3 Electrophoresis 
 
Gels were set in Mini-PROTEAN 3 electrophoresis cell chamber (see section 2.1.4), filled 
with Tris-glycine gel running buffer (see section 2.6.1.1). The power supply Power Pac 
300 (see section 2.1.4) was first set to constant voltage at 90 V until samples reached the 
separating gel then the voltage was raised to 120 V. 
 
2.6.2 Tris-tricine gels 
 
2.6.2.1 Materials 
 
 10-20% Tris-tricine gel (Invitrogen) 
 Tris-tricine gel running buffer: 
 100 mM Tris; 100 mM tricine; 0.1% SDS in dH2O 
 
2.6.2.2 Electrophoresis 
 
Pre-cast Tris-tricine gel was put into X Cell Sure LockTM Mini cell chamber (see section 
2.1.4). The gel chamber was filled with Tris-tricine gel running buffer (see section 2.6.2.1), 
and the gel was run at constant voltage as described above (see section 2.6.1.3). 
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2.6.3 Modified Tris-bicine-urea gel 
 
2.6.3.1 Materials 
 
 Separating gel buffer: 
 1.6 M Tris; 0.4 M H2SO4 in dH2O 
 Spacer gel buffer: 
 0.8 M Bis-tris; 0.2 M H2SO4 in dH2O 
 Stacking gel buffer: 
 0.72 M Bis-tris; 0.32 M bicine in dH2O 
 Acrylamide (BIO-RAD): 
 40% (w/v) Acrylamide/ bis-acrylamide 19:1 in dH2O 
 APS: 
 See section 2.6.1.1 
 20% SDS: 
 20% SDS in dH2O 
 Urea 
 TEMED 
 See section 2.6.1.1 
 Cathode buffer: 
 0.2 M Bicine; 0.25% SDS; 0.1 M NaOH in dH2O 
 Anode buffer: 
 0.2 M Tris; 50 mM H2SO4 in dH2O 
 
 
2.6.3.2 Gel preparation 
 
For one thick (1.5 mm) long gel: 
 
separating gel spacer gel stacking gel 
urea 4.8 g - - 
40% acrylamide 2.75 ml 300 µl 675 µl 
separating gel buffer 2.5 ml - - 
spacer gel buffer - 1 ml - 
stacking gel buffer - - 1.5 ml 
20% SDS 50 µl 10 µl 15 µl 
dH2O 1 ml 680 µl 740 µl 
APS 40 µl 8 µl 18 µl 
TEMED 5 µl 2 µl 6 µl 
 
The length of the separating gel, spacer gel, and stacking gel were respectively, 6.7 cm; 
1.25 cm and 1.7 cm. 
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2.6.3.3 Electrophoresis 
 
Modified Tris-bicine-urea gel was put into Mighty small II for 8x9CM cell chamber (see 
section 2.1.4). The inner gel chamber was filled with cathode buffer whereas the outer gel 
chamber was filled with anode buffer (see section 2.6.3.1). The power supply (EPS) (see 
section 2.1.4) was first set to 90 V until the samples reached the separating gel. Then the 
voltage was raised to 130 V. 
 
 
 
2.7 Western Blotting 
 
2.7.1 Materials 
 
 Blotting buffer: 
 25 mM Tris; 20 mM glycine in dH2O 
 Blocking buffer: 
 0.2% I-Block (Tropix); 0.1% tween-20 in PBS 
 TBST: 
 10 mM Tris pH 7.4; 150 mM NaCl; 0.1% tween-20 in dH2O 
 Sodium azide solution: 
 5% Sodium azide in dH2O 
 Filterpaper (Schleicher&Schuell) 
 Immobilon-P (PVDF transfer membrane) (Millipore) 
 Protran (Nitrocellulose transfer membrane) (Schleicher&Schuell) 
 ECL, western blotting detection reagent (Amersham Biosciences) 
 ECL plus, western blotting detection reagent (Amersham Biosciences) 
 Western-Star, protein detection kit (Tropix) 
 Super RX, Fuji Medical X-Ray film (Fujifilm) 
 
 
 
2.7.2 Blotting procedure 
 
PVDF transfer membrane was soaked in isopropanol and washed with dH2O before 
soaking in blotting buffer (see section 2.7.1). For detection of the Aβ and Aβ-like peptides, 
a nitrocellulose transfer membrane was used instead of PVDF. Nitrocellulose membrane 
was soaked directly in blotting buffer. Gels were carefully removed from the plates. The 
transfer membrane was placed on the gel between two filter papers (see section 2.7.1) 
soaked with blotting buffer and one sponge on both sides and placed on the transfer 
membrane. The sandwich were put in the Mini Trans-Blot cell transfer chamber (see 
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section 2.1.4) filled with blotting buffer and with an ice cube block. The proteins were 
transferred from the gel to the transfer membrane for 1 hour at constant 400 mA. 
 
 
2.7.3 Blocking procedure 
 
The transfer membrane was blocked for 1 hour at room temperature in blocking buffer 
(see section 2.7.1) to minimize unspecific antibody binding. Nitrocellulose membranes 
used for the detection of the Aβ and Aβ-like peptides were boiled for 5 min in PBS before 
blocking to increase the signal. 
 
2.7.4 Primary antibody incubation 
 
Each primary antibody was diluted as described (see sections 2.4.1 and 2.4.2) in blocking 
buffer with 0.05% sodium azide (see section 2.7.1). Transfer membranes were incubated 
with the appropriate first antibody overnight at 4°C with shaking. 
 
 
2.7.5 Secondary antibody incubation 
 
After the incubation with the primary antibody, the membrane was washed 5 times with 
TBST (see section 2.7.1) for 5 min each wash. After washing the membrane was 
incubated with the appropriate horseradish peroxidase (HRP)-conjugated second antibody 
at the optimum dilution in TBST (see section 2.4.3) for 1 hour at room temperature. For 
detection of the Aβ and Aβ-like peptides, the nitrocellulose transfer membrane was 
incubated with alkaline phosphatase (AP)-conjugated secondary antibody at the optimum 
dilution in TBST (see section 2.4.3). After the incubations with the secondary antibodies, 
membranes were washed 5 times with TBST for 5 min each wash. 
 
 
2.7.6 Detection 
Proteins were visualized by enhanced chemiluminescence (ECL) following the 
manufacturer’s protocol. ECL plus reagent (see section 2.7.1) was used to detect CD44-
ICD according to the manufacturer’s instructions. The secreted Aβ and Aβ-like peptides 
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were detected by the Western-Star kit (see section 2.7.1) following the manufacturer’s 
instructions. The signals were exposed on X-ray films for an appropriate time and the films 
were developed using a film developer machine (see section 2.1.4). 
 
 
 
2.8 Sandwich immunoassay 
 
2.8.1 Materials 
 
 ECL-blocking buffer: 
 PBS; 0.05% tween 20; 0.5% BSA 
 Washing buffer I: 
 PBS; 0.05% tween 20 
 Washing buffer II: 
 PBS 
 2D8-Biotin: 
 See section 2.4.1 
 Aβ38-Sulpho-Ruthenium-tag antibody: 
 See section 2.4.1 
 Aβ40-Sulpho-Ruthenium-tag antibody: 
 See section 2.4.1 
 Aβ42-Sulpho-Ruthenium-tag antibody: 
 See section 2.4.1 
 Synthetic Aβ38, Aβ40 and Aβ42 peptides (Bachem) 
 MSD read buffer T (4x) with surfactant (MSD) 
 
 
 
2.8.2 Sandwich immunoassay 
 
The Aβ40 and Aβ42 antibodies (see section 2.4.1) were labelled with a Sulpho-
Ruthenium-tag following the manufacturer’s protocol. Streptavidin-coated 96-well plates 
(see section 2.1.5) were blocked for 30 min at room temperature with 100 µl of blocking 
buffer (see section 2.8.1). 100 µl of capture antibody 2D8-biotin (see section 2.4.1) diluted 
in blocking buffer were added to the plate and incubated for one hour at room 
temperature. Unbound 2D8-biotin antibody was removed by washing the plate twice with 
100 µl of washing buffer I (see section 2.8.1). 75 µl of the sample and synthetic Aβ 
peptides were added to each well (for detection of Aβ40 species media was diluted 1:10 in 
DMEM plus Pen/Strep (see section 2.3.1)). The synthetic peptides were diluted in DMEM 
plus Pen/Strep to 1 µg/µl and then further serially diluted 1:3 down to 370 pg/ml. Then 25 
µl of the corresponding detection antibodies diluted in blocking buffer (see section 2.8.1) 
MATERIALS AND METHODS 
 62 
were added to the wells. The plate was incubated for 2 hours at room temperature on a 
shaker. Wells were washed with 100 µl of washing buffer I and washing buffer II two times 
each. 100 µl of 1x read buffer was added to each well (see section 2.8.1). Light emission 
at 620 nm was measured using the MSD Sector Imager 2400 reader (see section 2.1.5) 
and the concentrations of the Aβ peptides were calculated using the MSD Discovery 
workbench software (see section 2.1.5). For statistical analysis of the data Graph Pad 
Prism Software was used (see section 2.1.5).  
 
 
 
2.9 Mass Spectrometry (MS) 
 
2.9.1 Materials 
 
Protein G Sepharose (PGS) (GE Healthcare) 
 MS matrix: 
 Trifluoroacetic acid/water/acetonitrile (1/20/20) 
 MS IP buffer: 
 140 mM NaCl; 0.1% N-Octyl glucopiranoside; 10 mM Tris-HCl pH 8.0; 5 mM EDTA 
 
 
2.9.2 Mass spectrometry analysis 
 
Media from HEK/sw cells stably expressing the different H6X-PS1 constructs (see section 
2.2.6.1) treated with the different γ-secretase modulators (GSM) for 8h and 48 hours (233) 
were recollected to analyse the different Aβ species by MS. For that purpose, conditioned 
media was precleareded with PGS (see section 2.5.3.1) for 30 min at 4°C shaking and 
immunoprecipitated for Aβ peptides with antibody 4G8. Beads were washed with MS IP 
buffer (see section 2.5.3.1) for four times and two washes with dH20. Water was aspirated 
and the beads were allowed to dry for at least 20 min. 10 µl of the matrix (see section 
2.9.1) were added to the beads and 0.8 µl were added to the sample plate (see section 
2.1.6). This step was done up to six times. Samples were measured in the mass 
spectrometer (see section 2.1.6). Data were analysed with Data Explorer TM (see section 
2.1.6) 
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3 Results 
 
3.1  Most PS1 G382 mutants do not undergo endoproteolysis 
and do not support APP processing  
 
In order to investigate the functional role of glycine 382 of the PS1 GxGD motif, a site-
directed mutagenesis approach was used. The glycine residue was substituted by 
alanine, isoleucine, proline, tryptophan, lysine and aspartate to cover a wide range of 
different side chains (figure 14). To allow experimental flexibility, cDNA constructs 
encoding these PS1 mutations were created with an N-terminal Hexahistidine-Xpress tag 
(H6X) in addition to untagged variants.  
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Schematic depiction of PS1 and the mutations introduced into the GxGD motif at G382. 
TMDs harbouring the active site aspartates (D) are highlighted in green.  
 
The H6X-tagged constructs were stably expressed in human embryonic kidney 293 cells 
stably expressing APP carrying the Swedish mutation (HEK/sw cells). Lysates of these 
cells were used to verify the expression of the PS1 G382 mutants as well as γ-secretase 
complex formation. HEK cells have been widely used to study the processing of APP 
(36,70,75,272) and to characterize the α-, β-secretase and γ-secretase activities 
(36,101,139,192,273,274). For these reasons and also because HEK cells are easier to 
transfect than neuronal cell lines, this cells were used to stably express the H6X-PS1 
G382 mutants.  
 
As shown in figure 15 (panel A), γ-secretase complex formation was found to be normal 
as judged from the unaltered maturation of NCT. Maturation of NCT only takes place 
when the γ-secretase components are correctly assembled, allowing the complex to leave 
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the ER and to traffic to the Golgi apparatus where NCT becomes fully mature by complex 
glycosylation.  
 
Overexpression of the different PS1 constructs causes a reduction in the levels of 
endogenous PS1NTF demonstrating that endogenous PS1 has been replaced by the 
different PS1 constructs (figure 15 panel B). PS replacement is a well-established 
phenomenon, which demonstrates complex formation of PS with the other γ-secretase 
subunits (134,275). One striking feature that was observed is that endoproteolysis of the 
H6X-PS1 G382 mutants into NTF and CTF is strongly impaired similar to the H6X-PS1 
D385A. This active site mutant is unable to undergo endoproteolysis and is not able to 
process APPsw as evident from the strong accumulation of APPCTFs and the strong 
reduced Aβ secretion in the conditioned media. With regard to PS1 endoproteolysis, only 
the H6X-PS1 G382A mutant was endoproteolysed as evident from the generation of 
PS1NTF and PS1CTF (panel B and C).  
 
With regard to γ-secretase activity, most of the H6X-PS1 G382 mutants are unable to 
process APP as judged from accumulation of the APPCTFs and the strongly reduced Aβ 
production in the conditioned media (figure 15 panels D and E) similar to the H6X-PS1 
D385A. Again, the only exception is H6X-PS1 G382A mutant in which the APPCTFs are 
processed and the Aβ peptide is detected in the conditioned media (Figure 15 panels D 
and E). Quantitation further confirmed the loss of function of most of the PS1 G382 
mutants (figure 16). As observed in figure 15, panel E, PS1 G382I also secreted Aβ into 
the media. This Aβ production was probably due to the presence of residual endogenous 
PS1 (figure 15 panel B). In section 3.2.1 using PS1/PS2 -/- MEF cells it was confirmed 
that PS1 G382I is indeed inactive and does not secrete Aβ peptide. Taken together these 
results suggest that changing the glycine to another amino acid does not affect γ-
secretase complex formation but has an impact on endoproteolysis of PS1 and γ-
secretase activity. When the side chain change generated is minor, then both 
endoproteolysis and proteolytic activity are supported, like in the case of the H6X-G382A 
mutant, in which a hydrogen atom (the side chain of the glycine) is changed to a methyl 
group (the side chain of the alanine).  
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Figure 15. Cell lysates from HEK/sw cells stably expressing the indicated H6X-tagged PS1 
constructs were analysed for NCT maturation by immunoblotting with antibody N1660 (panel A), for 
PS1 expression and endoproteolysis with antibodies PS1N and 3027 to detect PS1NTF and PS1CTF 
respectively (panels B and C) and for APP processing with antibodies 6687 to detect APPCTFs 
(panel D). Aβ was detected by combined immunoprecipitation/immunoblotting with antibodies 
3552/6E10 (panel E). γ-Secretase components were separated by a 10% Tris-glycine-urea gel, 
while APPCTF and total Aβ were separated by a 10-20% Tris-tricine gel. 
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Figure 16: Signal intensity of APPCTFs accumulated by the different H6X-PS1 G382 mutants in 
HEK/sw cells and normalised by NCTmat protein levels. The signal intensity of APPCTFs produced by 
H6X-PS1 wt was set to 100%. Data were statistically analysed by paired two-tailed student’s t test. 
(* p<0.05). The data are representative of three independent experiments (n=3). 
 
 
 
 
 
 
3.1.1 PS1 G382A mutant produces AICD and Aβ in vitro 
 
To further confirm these results, selected H6X-PS1 G382 mutants were analysed in a cell 
free γ-secretase assay with a recombinant APP substrate, C100-His6 (see section 2.5.4.1). 
γ-Secretase complexes from cells stably expressing H6X-PS1 wt, H6X-PS1 D385A, H6X-
PS1 G382A, and the strong mutants H6X-PS1 G382P and H6X-PS1 G382K were isolated 
by immunoprecipitation using an antibody against the Xpress epitope in order to avoid the 
potential interference by immunoprecipitation of an endogenous complex. As shown in 
figure 17, in agreement with the previous result, H6X-PS1 wt and the H6X-PS1 G382A 
mutant are able to process the recombinant APP C100-His6 substrate and thereby to 
produce AICD and Aβ. In the case of the H6X-PS1 G382A mutant, processing of C100-
His6 was somewhat diminished since the levels of AICD and Aβ produced by this mutant 
were lower compared to the respective levels produced by H6X-PS1 wt. This suggests 
that the change from glycine to alanine partially impairs the activity of the protease. Both 
H6X-PS1 G382P and H6X-PS1 G382K mutants showed only residual γ-secretase activity, 
if any, also in agreement with the previous result obtained in living cells. Thus, only the 
H6X-PS1 G382A mutant and the H6X-PS1 wt were active in vitro. Taken together, this 
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assay confirms the partial activity of the H6X-PS1 G382A mutant and the inactivity of the 
H6X-PS1 G382P and H6X-PS1 G382K mutants observed in figure 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. γ-Secretase complexes from the HEK/sw cells stably expressing the indicated constructs 
were immunoprecipitated with anti-Xpress antibody and incubated with recombinant C100-His6 
substrate overnight at 37°C. Samples were separated on a 10-20% Tris-tricine gel and AICD and 
Aβ were detected by immunoblotting with antibodies 6687 (panel A) and 6E10 (panel B) 
respectively. Asterisk denotes a band produced probably by the action of other proteases on C100-
His6. 
 
 
 
 
3.1.2 PS1 G382A alters the cleavage specificity of the γ-cleavage sites 
 
Because H6X-PS1 G382A supports APP processing and generates Aβ, the potential 
impact of this mutation on the formation of the different Aβ species was studied next. 
Since glycine 384 of the GxGD motif was previously identified as a FAD-associated 
mutation (G384A), which strongly elevates Aβ42 production (148), it was next investigated 
whether PS1 G382A could also alter the γ-cleavage specificity and thereby increase the 
production of long Aβ species. 
 
Aβ species from conditioned media from HEK/sw cells stably transfected with H6X-PS1 wt, 
H6X-PS1 D385A and H6X-PS1 G382A were isolated by immunoprecipitation and 
separated by a Tris-bicine-urea gel system, which allows the separation of the different Aβ 
species (276). The qualitative Aβ peptide analysis of the media showed a slight increase 
in the short Aβ38 species for H6X-PS1 G382A in comparison to H6X-PS1 wt whereas a 
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decrease in Aβ39 was observed for H6X-PS1 G382A in comparison to H6X-PS1 wt (figure 
18 panel A). Although this Tris-bicine-urea gel system is not sensitive enough to detect 
small changes in Aβ species, the analysis indicated also an increase in longer species 
(Aβ42/Aβ43) although not as strong as for the FAD PS1 L166P mutation (figure 18 panels 
A and B). In order to use a more sensitive assay and to verify this finding, the same 
samples from H6X-PS1 wt and H6X-PS1 G382A were subjected to a sandwich 
immunoassay allowing the quantification of the levels of the Aβ species, Aβ38, Aβ40 and 
Aβ42, present in the conditioned media, as well as to mass spectrometry analysis (MS). 
Data from the Aβ sandwich immunoassay showed for the H6X-PS1 G382A mutant an 
increase in the Aβ38/Aβtotal ratio, and a slight increase in Aβ42/Aβtotal ratio (figure 19). In 
the H6X-PS1 G382A mutant, Aβ40/Aβtotal ratio was slightly lower than H6X-PS1 wt (figure 
19). This is consistent with the partial loss of γ-secretase activity of this mutant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Panel A, Aβ species from conditioned media from HEK/sw cells stably expressing H6X-
PS1 wt and H6X-PS1 G382A were immunoprecipitated with antibody 3552 overnight at 4°C. Panel 
B, Aβ species from conditioned media from HEK/sw cells stably expressing H6X-PS1 wt, H6X-PS1 
D385A and H6X-PS1 G382A and PS1 L166P were immuprecipitated with antibody 3552 overnight 
at 4°C. Immunoprecipitates were subjected to Tris-bicine-urea SDS-PAGE to separate the different 
Aβ species. Aβ species were detected by immunoblotting with antibody 6E10. 
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Figure 19: Sandwich immunoassay of Aβ species isolated from conditioned media of HEK/sw cells 
media stably expressing H6X-PS1 wt and H6X-PS1 G382A. Aβ38/Aβtotal, Aβ40/Aβtotal, 
Aβ42/Aβtotal ratios were determined. Data represent the average of five independent experiments. 
Error bars indicate the standard error of the mean. Statistical significance was calculated by paired 
two-tailed student’s t test (** p<0.01). 
 
 
 
MS analysis reveales the different Aβ species generated in each sample although is not a 
quantitative method (figure 20). In the mass spectrum of H6X-PS1 G382A an extra peak 
corresponding to the Aβ43 species was observed (figure 20 panel B). This species was 
not observed for H6X-PS1 wt (figure 20 panel A). In addition, the Aβ39 peak present in the 
mass spectrum for H6X-PS1 wt was almost not detected for H6X-PS1 G382A in 
agreement with the Tris-bicine-urea gel analysis (figure 18). Therefore, the H6X-PS1 
G382A mutant produces an additional Aβ longer species, Aβ43. This suggests that the 
increase of longer species observed for this mutant that was indicated by the Tris-bicine-
urea gel analysis (Figure 18 panels A and B) is due to an increased production of Aβ43. 
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Figure 20. Representative MALDI-TOF MS of Aβ peptides immunoprecipitated from conditioned 
media of HEK/sw cells expressing H6X-PS1 wt (Panel A) and H6X-PS1 G382A (Panel B). Arrows 
indicate the major peak changes. 
 
 
 
 
 
 
 
 
 
Table 4. Calculated and observed masses of the different Aβ species found in the media of 
HEK/sw cells expressing H6X-PS1 wt and H6X-PS1 G382A. The calculated masses were predicted 
by GPMAW (lighthouse) program. 
 
 
 
3.1.3 PS1 G382A mutant shows an altered response to NSAIDs 
 
It has been shown previously that a subset of NSAIDs typically causes a decrease in 
Aβ42 levels and an increase in Aβ38 levels while Aβ40 levels remain largely unaffected 
suggesting that these cleavages are interdependent (233). However, a recent study of 
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Aβ39 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV 4230.73 4228.69 4230.67
Aβ40 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 4329.86 4328.50 4330.08
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Aβ43 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT 4615.21 - 4614.78
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PS1 FAD mutations revealed that the Aβ38/Aβ42 production is in fact not coupled (277) 
(278).  Moreover, it was found that many of the FAD mutants are less responsive to 
NSAIDs (277-279).    
 
It was therefore next investigated whether and how the H6X-PS1 G382A mutant might 
change the specificity of the γ-cleavage in response to NSAIDs. HEK/sw cells stably 
expressing H6X-PS1 wt and H6X-PS1 G382A were treated with sulindac sulfide (Sul) and 
flurbiprofen (Flu), two well characterized NSAIDs, which modulate the activity of γ-
secretase thereby increasing Aβ38 and reducing Aβ42 (233,280). In addition, cells were 
treated with fenofibrate (Fen) a lipid-regulating drug which has been shown to act as an 
inverse γ-secretase modulator by increasing Aβ42 and decreasing Aβ38 (270) and with 
naproxen (Nap), an NSAID which does not affect modulation of γ-secretase (233). Cells 
were pretreated with the drugs for 24 hours, then media were changed and the incubation 
in the presence of the drugs was continued for another 24 hours (233). Conditioned media 
were then collected and immunoprecipitated Aβ species were separated on a Tris-bicine-
urea gel system (Figure 21). The concentrations used for these γ-secretase modulators 
(GSMs) were 40 µM for Sul, 150 µM for Flu, 100 µM for Fen and 200 µM for Nap 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. HEK/sw cells expressing the indicated PS1 constructs were treated with Sul (40 µM) 
and Flu (150 µM) or left untreated (DMSO). After the drug treatment, conditioned media were 
collected and subjected to immunoprecipitation of Aβ with polyclonal antibody 3552. 
Immunoprecipitated Aβ species were separated on a Tris-bicine-urea gel system and identified by 
immunoblotting with monoclonal antibody 6E10. Aβ38, Aβ40 and Aβ42 peptide standards were 
loaded in parallel (M) 
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As shown in figure 21, in H6X-PS1 wt cells, the treatment with Sul and Flu lowered the 
amount of Aβ42 and increased the amounts of Aβ38 species produced in comparison to 
DMSO-treated cells. Likewise, H6X-PS1 G382A showed a decrease in long Aβ species 
(Aβ42/Aβ43) in response to the same GSMs. However, this decrease was not 
accompanied with a concomitant increase in Aβ38 species in the case of Flu treatment 
and with only a small increase of Aβ38 in the case of Sul treatment. To further confirm this 
qualitative result, aliquots of the same media were subjected to an Aβ sandwich 
immunoassay to allow quantitation and to MS analysis. 
RESULTS 
 73
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Effect of Sul (40 µM) and Flu (150 µM) treatment on Aβ generation in HEK/sw cells 
expressing H6X-PS1 wt and H6X-PS1 G382A. Aβ38, Aβ40 and Aβ42 levels in conditioned media 
from HEK/sw cells stably expressing H6X-PS1 wt and H6X-PS1 G382A were measured by 
sandwich immunoassay and the Aβ38/Aβtotal, Aβ40/Aβtotal, Aβ42/Aβtotal ratios were determined. 
Statistical analysis of the data was performed by paired two-tailed student’s t test. (* p<0.05; ** 
p<0.01; *** p< 0.001). The data are representative of three independent experiments (n=3). 
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As shown in figure 22, H6X-PS1 G382A had a typical response to Sul (i.e. an increase of 
the Aβ38/Aβtotal ratio and a decrease of the Aβ42/Aβtotal ratio) although its response was 
not as strong as for H6X-PS1 wt (Figure 22, panels A, B and C). In contrast, H6X-PS1 
G382A had a robust decrease in the Aβ38/Aβtotal ratio in response to Flu treatment 
(figure 22 panel D) whereas the decrease in the Aβ42/Aβtotal ratio was comparable to the 
decrease observed for H6X-PS1 wt (figure 22 panel F). Moreover, the Aβ40/Aβtotal ratio 
was apparently also affected in the H6X-PS1 G382A mutant in response to Flu treatment 
consistent with the Tris-bicine-urea gel analysis (figure 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.Representative MALDI-TOF MS of Aβ peptides immunoprecipitated from media from 
HEK/sw cells expressing H6X-PS1 wt treated with DMSO (panel A) with Sul (panel B) and with Flu 
(panel C). Arrows indicate major peak changes. 
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Figure 24.Representative MALDI-TOF MS of Aβ peptides immunoprecipitated from conditioned 
media from HEK/sw cells expressing H6X-PS1 G382A treated with DMSO (panel A) with Sul (panel 
B) and with Flu (panel C). Arrows indicate major peak changes. 
 
 
MS analysis confirmed the typical NSAID response observed for H6X-PS1 wt (figure 23) 
with a decrease in longer Aβ species and an increase in the shorter ones (figure 23 
panels B and C). Interestingly Flu causes an increase in Aβ37 in H6X-PS1 wt besides the 
increase in Aβ38. H6X-PS1 G382A had a typical response to NSAIDs for Sul treatment 
(figure 24 panel B) whereas a decrease in shorter Aβ species as well as longer Aβ 
species was observed for Flu treatment (figure 24 panel C). 
 
The response to Fen (100 µM) and Nap (200 µM) treatment of the H6X-PS1 G382A was 
analysed next. Cells were treated for 8 hours with Fen instead of the usual 48 hours due 
to the fact that Fen showed high toxicity for HEK cells at 100 µM in a 16 hours incubation. 
As shown in figure 25 for both H6X-PS1 wt and H6X-PS1 G382A a reduction in Aβ38 and 
Aβ40 species was seen upon Fen treatment with a concomitant increase in Aβ42/Aβ43 
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species. Nap treatment did not change any species neither in H6X-PS1 wt nor in H6X-PS1 
G382A. To further confirm this qualitative result, and due to the fact that the Tris-bicine-
urea gel system is not sensitive enough to detect small changes in Aβ species, aliquots of 
the same conditioned media was subjected to a sandwich immunoassay to allow 
quantitation of Aβ species and to MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. HEK/sw cells expressing the indicated PS1 constructs were treated with Fen (100 µM) 
and Nap (200 µM) or left untreated (DMSO). After the treatment, conditioned media were 
recollected and subjected to immunoprecipitation for Aβ with polyclonal antibody 3552. Aβ species 
were separated on a Tris-bicine-urea gel system and identified by immunoblotting with monoclonal 
antibody 6E10. Aβ38, Aβ40 and Aβ42 standards were loaded in parallel (M) 
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Figure 26. Effect of Nap (200 µM) and Fen (100 µM) treatment in HEK/sw cells expressing H6X-
PS1 wt and H6X-PS1 G382A. Aβ38, Aβ40 and Aβ42 levels in conditioned media from HEK/sw cells 
stably expressing H6X-PS1 wt and H6X-PS1 G382A were measured by the Aβ sandwich 
immunoassay and the Aβ38/Aβtotal, Aβ40/Aβtotal, Aβ42/Aβtotal ratios were determined. Data were 
statistically analysed by paired two-tailed student’s t test. (* p<0.05; ** p<0.01; *** p< 0.001). The 
data are representative of three independent experiments (n=3). 
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Figure 27.Representative MALDI-TOF MS of Aβ peptides immunoprecipitated from conditioned 
media of HEK/sw cells expressing H6X-PS1 wt treated with DMSO (panel A) or Nap (Panel B), and 
cells expressing H6X-PS1 G382A treated with DMSO (panel C) and with Nap (panel D). Arrows 
indicate the major peak changes. 
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Figure 28.Representative MALDI-TOF MS of Aβ peptides immunoprecipitated from media from 
HEK/sw cells expressing H6X-PS1 wt, treated with DMSO (panel A) and Fen (Panel B), and H6X-
PS1 G382A treated with DMSO (panel C) and with Fen (panel D). Arrows indicate the major peak 
changes. 
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As shown in figure 26, both H6X-PS1 wt and H6X-PS1 G382A showed a decrease in the 
Aβ38/Aβtotal and Aβ40/Aβtotal ratios (figure 26 panels D and E) and both showed an 
increase in Aβ42/Aβtotal ratio (figure 26 panel F) in response to Fen treatment. On the 
other hand, Nap caused an increase in the Aβ38/Aβtotal ratio for H6X-PS1 wt whereas, 
H6X-PS1 G382A showed a decrease in the Aβ38/Aβtotal ratio and an increase in the 
Aβ40/Aβtotal ratio compared to H6X-PS1 wt. The Aβ42/Aβtotal ratio, however, did not 
significantly change for H6X-PS1 wt and H6X-PS1 G382A (figure 26 panels A, B and C).  
 
These results were confirmed by MS analysis. Nap treatment caused a relative increase 
in shorter Aβ species (Aβ37 and Aβ38) for H6X-PS1 wt (figure 27 panels A and B). In 
contrast, in response to Nap treatment a decrease in Aβ38 is observed in H6X-PS1 
G382A (figure 27 panels C and D). As expected, Fen treatment increased long Aβ42 
species decreasing the levels of Aβ38 for H6X-PS1 wt (figure 28 panels A and B). 
Strikingly, for H6X-PS1 G382A in addition to a relative increase in Aβ42 species in 
response to Fen treatment a large increase in Aβ43 species was observed (figure 28 
panels C and D) suggesting a different behaviour between H6X-PS1 wt and H6X-PS1 
G382A with regard to Fen treatment. 
 
Taken together, these results suggest that the PS1 G382A mutant has an altered 
response to some GSMs on the generation of the Aβ species than PS1 wt. The data 
further suggests that the production of Aβ38 and Aβ42 upon NSAID treatment is not 
coupled in PS1 mutants in agreement to the findings with PS1 FAD mutations (277). 
 
 
 
3.2 Impact of PS1 G382 mutants on the processing of other γ-
secretase substrates 
 
As shown in the previous experiments, APP processing is affected by the mutagenesis of 
the N-terminal glycine of the GxGD motif of PS1. When this glycine is changed to an 
amino acid with a large side chain, APP processing is generally impaired, whereas when 
the change is minor, processing can occur but with a lesser efficiency. It was then 
investigated whether the mutagenesis of this residue has also an impact on processing of 
other γ-secretase substrates. In order to address this question, mouse embryonic 
fibroblasts (MEF) cells derived from PS1/PS2 -/- knockout mice were used (268) where no 
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endogenous PS is present that could interfere with the result. Untagged PS1 G382 mutant 
cDNAs were transiently co-transfected in PS1/PS2 -/- MEF cells with the cDNAs encoding 
for the substrate under investigation. The substrates used for this purpose were APP, 
Notch1, Notch2, Notch3, Notch4 and CD44 as these proteins have been previously shown 
to be processed by γ-secretase (191,192,204). cDNAs of PS1 wt, PS1 D385A as well as 
empty vector were generally co-transfected to serve as a positive and negative control 
respectively. 
 
 
3.2.1 PS1 G382A supports processing of APPsw-6myc in PS1/PS2 -/- 
MEF cells 
 
PS1/PS2 -/- MEF cells have been shown to be a reliable system to study PS mutations in 
a PS free background (125,149,192,281). In order to first verify the results obtained in the 
HEK/sw background, cDNAs encoding the PS1 G382 mutants were transiently co-
transfected with APPsw-6myc into PS1/PS2 -/- MEF cells. APPsw-6myc is an APP 
molecule that harbors the Swedish mutation and is C-terminally tagged with 6myc 
epitopes (265). 
 
Following transient transfection, total cell lysates were analysed by immunoblotting. NCT 
maturation was rescued upon expression of all PS1 proteins, indicating a normal γ-
secretase complex formation (figure 29 panel A). As shown in figure 29, all transfected 
proteins were robustly expressed. PS1 wt and PS1 G382A were endoproteolysed to NTF 
and CTF whereas all other mutants remained as uncleaved holoprotein (Figure 29 panels 
B and C). This result is in agreement with the observations in the HEK/sw cells described 
above. To investigate the processing of APPsw-6myc, production of AICD and secretion 
of Aβ peptide were examined. The 6myc-tagged AICD can be analysed in this 
experimental setting because it is more stable than the untagged AICD (265). AICD was 
only generated when APPsw-6myc is co-transfected with PS1 wt and PS1 G382A (figure 
29 panels D and E and figure 30). In addition, PS1 wt expression strongly reduced the 
accumulation of APPCTFs. In contrast, PS1 G382A was not able to rescue APPCTFs 
accumulation (figure 29 panel D) suggesting that PS1 G382A mutant is only partially 
active. Aβ peptide was only secreted when PS1 wt and PS1 G382A were present (figure 
29 panel E). These data fully confirm the observation made with the G382 mutant in the 
background of the HEK/sw system. 
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Figure 29. PS1 G382A mutants do not process APPsw-6myc with the exception of PS1 G382A. 
PS1/PS2 -/- MEF cells were transiently transfected with the indicated PS1 constructs. Cell lysates 
were analysed for PS1 expression and γ-secretase complex formation (panel A) by immunoblotting 
using antibodies N1660 for the detection of NCT and PS1N and 3027 for the detection of PS1NTF 
and PS1CTF respectively (panels B and C). APP processing was analysed in panel D, AICD 
formation was detected with antibody 9E10 against the myc tag. Secreted Aβ was analysed by 
combined immunoprecipitation/immunoblotting using polyclonal and monoclonal anti-Aβ with 
antibodies 3552/6E10. γ-Secretase components and AICD were separated by 10% Tris-glycine-
urea SDS-PAGE. Aβ was separated in a 10-20% Tris-tricine SDS-PAGE. 
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Figure 30: Signal intensity of AICD produced by PS1 G382A in PS1/PS2 -/- MEF cells. The 
intensity of the AICD bands were quantified and normalised by NCTmat protein levels. The 
normalised AICD produced by PS1 wt were set to 100%. %. Data were statistically analysed by 
one-way ANOVA with Dunnet’s post correction test for comparison of multiple samples to a control 
(PS1 wt) (** p<0.01). The data are representative of three independent experiments (n=3). 
 
 
 
 
3.2.2 PS1 G382A supports processing of Notch1 in PS1/PS2 -/- MEF 
cells 
 
Next, the PS1 G382 mutants were tested for their capability to process the most important 
physiological γ-secretase substrate, Notch1. PS1/PS2 -/- MEF cells were transiently co-
transfected with cDNAs encoding the PS1 G382 mutants and with cDNA encoding F-
NEXT, an extracellular truncated version of Notch1 tagged N-terminally with a Flag-
epitope and C-terminally with a 6myc epitope to facilitate the analysis of the cleavage 
products (267). As described before, total cell lysates were analysed by immunoblotting. 
All transfected proteins were strongly expressed and NCT maturation was rescued upon 
PS1 expression (figure 31 panel A). PS1 wt and PS1 G382A mutants were 
endoproteolysed whereas other PS1 mutants remained as uncleaved holoprotein (figure 
31 panels B and C). As seen in the vector-transfected lane (figure 31), F-NEXT was not 
processed due to the absence of a fully γ-secretase complex in these cells but upon 
expression of PS1 wt and PS1 G382A NICD was produced and Nβ peptide was secreted 
to the media (figure 31 panels D, E, F and figure 32) although no reduction in the 
substrate levels is observed. This lack of reduction in the substrate levels observed in the 
PS1 wt lane is probably due to an excess of the substrate present in the cells that cannot 
be completely processed. As observed for APP, the other PS1 G382 mutants did not 
support F-NEXT processing. Thus, similar as for APP processing, only subtle changes in 
the GxGD motif are partially accepted for F-NEXT processing. 
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Figure 31. PS1 G382A mutants do not process F-NEXT with the exception of PS1 G382A. Panels 
A, B and C, lysates from cells transiently expressing the above PS1 constructs were analysed by 
immunoblotting for γ-secretase complex formation and PS1 endoproteolysis using N1660, PS1N 
and 3027 antibody. In Panel D, processing of F-NEXT was analysed by immunoblotting with 
antibody 9E10. Panel E, NICD was immunoblotted with cleaved Notch1 antibody, specific for 
NICD. Panel F, secreted Nβ peptide was analysed by immunoprecipitation with Flag M2 agarose 
and immunoblotting with Flag-M2 antibody. γ-Secretase components were separated by 10% Tris-
glycine-urea SDS-PAGE. NICD and F-NEXT were separated by 7% Tris-glycine SDS-PAGE. Nβ 
was separated by 10%-20% Tris-tricine SDS-PAGE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Signal intensity of NICD produced by PS1 G382A in PS1/PS2 -/- MEF cells. The 
intensity of the NICD bands were quantified and normalized by NCTmat protein levels. The 
normalized NICD levels produced by PS1 wt were set to 100%. Data were statistically analysed by 
one-way ANOVA with Dunnet’s post correction test for comparison of multiple samples to a control 
(PS1 wt) (** p<0.01). The data are representative of three independent experiments (n=3). 
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3.2.3 PS1 G382A supports Notch2 processing in PS1/PS2 -/- MEF cells 
 
Next it was investigated whether PS1 G382 mutants can process homologues of Notch1 
(see section 1.3.3.3.1). Notch2 was investigated first. PS1/PS2 -/- MEF were transiently 
co-transfected with cDNAs encoding the PS1 G382A mutant and PS1 G382P and PS1 
G382K as strong mutations, with cDNA encoding for mouse Notch2∆E. mNotch2∆E is the 
extracellular truncated version of mouse Notch2 tagged at the C-terminus with a 6myc 
epitope. Following transfection, total cell lysates were analysed as before. As expected, 
NCT maturation was rescued upon PS expression and PS1 wt and PS1 G382A 
underwent endoproteolysis, while the other two mutants did not (figure 33 panels A, B and 
C). As expected in the vector-transfected lane processing of mNotch2∆E was not 
observed, since no functional γ-secretase complex was present. This was reverted when 
PS1 wt and PS1 G382A mutant were present as NICD was produced (figure 33 panel D 
and figure 34). However, as for Notch1, neither PS1 G382P nor PS1 G382K rescued the 
processing of mNotch2∆E. Thus, only subtle changes, from a glycine to an alanine within 
the GxGD motif are accepted for mNotch2∆E processing. 
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Figure 33. PS1 G382A mutants do not process mNotch2∆E with the exception of PS1 G382A. 
Panels A, B and C, lysates from cells transiently expressing the PS1 constructs were analysed by 
immunoblotting for γ-secretase components using N1660, PS1N and 3027 antibodies. In Panel D, 
processing of mNotch2∆E was analysed by immunoblotting with antibody 9E10. Asterisks denote 
the cleaved Notch2 fragment. γ-Secretase components were separated by 10% Tris-glycine-urea 
SDS-PAGE. NICD and mNotch2∆E were separated by 7% Tris-glycine SDS-PAGE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Signal intensity of NICD produced by PS1 G382A in PS1/PS2 -/- MEF cells. The NICD 
bands intensity were quantified and normalised by NCTmat protein levels. The normalised NICD 
levels produced by PS1 wt were set to 100%. Data were statistically analysed by one-way ANOVA 
with Dunnet’s post correction test for comparison of multiple samples to a control (PS1 wt) (** 
p<0.01). The data are representative of three independent experiments (n=3). 
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3.2.4 PS1 G382A mutant supports processing of Notch3 in PS1/PS2 -/- 
MEF cells 
 
The capacity of the PS1 G382 mutants in processing of Notch3, another Notch1 
homologue, was investigated next. PS1/PS2 -/- MEF cells were transiently co-transfected 
with the same set of PS1 cDNAs as before and with the cDNA encoding the mouse 
mNotch3∆E, an extracellular truncated mouse version of Notch3 tagged at the C-terminus 
with a 6myc epitope (191). Following transfection, total cell lysates were analysed as 
before. All transfected proteins were robustly expressed. PS1 wt and PS1 G382A 
underwent endoproteolysis as expected and NCT maturation was rescued by the 
presence of PS1 (figure 35 panels A, B and C). In the vector-transfected lane due to the 
absence of an active γ-secretase complex no process of mNotch3∆E was observed. 
When PS1 wt and PS1 G382A were present this was reverted and NICD was produced 
(figure 35 panel D and figure 36). Thus again, only a minor change in the position 382 of 
presenilin from glycine to alanine allows processing to some extent. More drastic 
changes, like proline or lysine, interfere with processing. 
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Figure 35. PS1 G382A mutants do not process mNotch3∆E with the exception of PS1 G382A. In 
panels A, B and C, lysates from cells transiently expressing the above PS1 constructs were 
analysed by immunoblotting for γ-secretase components using N1660, PS1N and 3027 antibodies. 
In Panel D, processing of mNotch3∆E was analysed by immunoblotting with antibody 9E10. 
Asterisks denote the cleaved notch3 fragment. γ-Secretase components were separated by 10% 
Tris-glycine-urea SDS-PAGE. NICD and mNotch3∆E were separated by 7% Tris-glycine SDS-
PAGE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Signal intensity of NICD produced by PS1 G382A in PS1/PS2 -/- MEF cells. The NICD 
band intensities were quantified and normalized to NCTmat protein levels. The normalized NICD 
levels produced by PS1 wt were set to 100%. Data were statistically analysed by one-way ANOVA 
with Dunnet’s post correction test for comparison of multiple samples to a control (PS1 wt) (** 
p<0.01). The data are representative of three independent experiments (n=3). 
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3.2.5 PS1 G382 mutants do not support Notch4 processing in PS1/PS2 
-/- MEF cells 
 
The last Notch homologue to be investigated was Notch4. As before PS1/PS2-/- MEF 
cells were transiently co-transfected with the cDNAs encoding for the PS1 G382 mutants, 
and with cDNA encoding for mouse Notch4∆E, which is an extracellular truncated mouse 
version of Notch4 tagged at the C-terminus with 6myc epitopes (191). Following 
transfection, total cell lysates were analysed as before. As shown in figure 32 all 
transfected proteins were robustly expressed. As expected, the presence of PS1 restored 
NCT maturation suggesting normal γ-secretase complex formation. PS1 wt and PS1 
G382A, as before, were endoproteolysed (figure 37, panels A, B and C). Strikingly, only 
cells expressing PS1 wt allowed the generation of NICD, whereas cells expressing PS1 
G382A did not produce any NICD (figure 37, panels D, E and figure 38). This result 
suggests that G382 is indeed important for mNotch4∆E processing, since not even a 
minor change in this region of the GxGD motif allows the processing of this substrate. 
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Figure 37. PS1 G382A mutant does not process mNotch4∆E. Panels A, B and C, lysates from cells 
transiently expressing the above PS1 constructs were analysed by immunoblotting for γ-secretase 
components using N1660, PS1N and 3027 antibodies. In Panel D, processing of mNotch4∆E was 
analysed by immunoblotting with antibody 9E10. Asterisk denotes the cleaved Notch4 fragment. γ-
Secretase components were separated by 10% Tris-glycine-urea SDS-PAGE. NICD and 
mNotch4∆E were separated by 7% Tris-glycine SDS-PAGE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Signal intensity of NICD produced by PS1 G382A in PS1/PS2 -/- MEF cells. The NICD 
band intensities were quantified and normalised by NCTmat protein levels. The normalised NICD 
levels produced by PS1 wt were set to 100%. Data were statistically analysed by one-way ANOVA 
with Dunnet’s post correction test for comparison of multiple samples to a control (PS1 wt) (** 
p<0.01). The data are representative of three independent experiments (n=3). 
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3.2.6 PS1 G382 mutants do not support processing of CD44 in 
PS1/PS2-/- MEF cells 
 
Finally, it was investigated whether PS1 G382 mutants can process CD44. The cDNA of 
this construct encodes for an extracellular truncated version of CD44 with a Flag epitope 
at the N-terminus, which allows the analysis of the secreted CD44β peptide, and a 6myc 
epitope at the C-terminus to allow analysis of the CD44-ICD formation (192). This cDNA 
construct was co-transfected with the cDNAs encoding for the PS1 G382 mutants. As 
shown above, PS1 wt and PS1 D385A cDNAs as well as vector alone were co-transfected 
as controls. Following transfection, total cell lysates were analysed as before. As 
expected, endoproteolysis occurred in PS1 wt and PS1 G382A and the presence of the 
PS1 rescued the maturation of NCT suggesting normal γ-secretase complex formation 
(figure 39 panels A, B and C). In the vector-transfected lane, consistent with the absence 
of an active γ-secretase in PS1/PS2 -/- MEF cells, no CD44-ICD was observed and no 
CD44β was detected in the conditioned media. Only when PS1 wt was present this 
situation was reverted as CD44-ICD was produced and CD44β peptide was detected in 
the conditioned media (figure 39 panels E and F). Due to the weak intensity of the CD44-
ICD band, CD44β was used instead for quantitation. Quantitation of the experiment shows 
a reduction of CD44β peptide produced by PS1 G382A (figure 40). In contrast, all the PS1 
G382 mutants were inactive, suggesting that as also observed for mNotch4∆E, this 
glycine in position 382 of the GxGD motif is also crucial for CD44∆E-Flag processing. 
Thus, not even a subtle change of G382 to alanine allows the processing of this substrate.  
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Figure 39. PS1 G382A mutant does not process CD44∆E-Flag. Panels A, B and C lysates from 
cells transiently expressing the indicated PS1 constructs were analysed by immunoblotting for γ-
secretase components using N1660, PS1N and 3027 antibody. In Panel D, processing of CD44∆E-
Flag was analysed by immunoblotting with antibody 9E10. Panel E, CD44-ICD was detected by 
immunoprecipitation with anti c-myc agarose and immunoblotting with 9E10 antibody. Asterisk 
denotes CD44-ICD fragment. Panel F, secreted CD44β peptide was analysed by 
immunoprecipitation with Flag M2 agarose and immunoblotted with Flag M2 antibody. γ-Secretase 
components were separated by 10% Tris-glycine-urea SDS-PAGE. CD44CTFs and CD44-ICD were 
separated by 12% Tris-glycine SDS-PAGE. Nβ was separated by 10%-20% Tris-tricine SDS-
PAGE. 
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Figure 40: Signal intensity of CD44β produced by PS1 G382A in PS1/PS2 -/- MEF cells. The 
CD44β band intensities were quantified and normalised by NCTmat protein levels. The normalised 
NICD levels produced by PS1 wt were set to 100%. Data were statistically analysed by one-way 
ANOVA with Dunnet’s post correction test for comparison of multiple samples to a control (PS1 wt) 
(** p<0.01). The data are representative of three independent experiments (n=3). 
 
 
 
 
 
 
 
3.3 Proteasomal turn over of NICD generated by PS1 wt, PS1 
G382A and PS1 L383F is similar  
 
As shown in figure 31 and 32, PS1 G382A supports F-NEXT processing as it produces 
NICD, but the levels produced by the PS1 G382A mutant are reduced compared to the 
levels produced by PS1 wt. A much stronger processing reduction was observed for the 
PS1 L383F mutant where F-NEXT processing was strongly impaired (149). While it is 
plausible that the mutations reduce the cleavage efficiency of the enzyme, therefore the 
cleavage product obtained is reduced, another explanation could be that the mutations do 
not alter the efficiency of the enzyme but rather alter the cleavage site. If that is the case it 
is possible that the new N-terminal residue is a de-stabilizing residue targeting the 
resultant cleavage product to the proteasome for degradation according to the “N-end 
rule” (282) (figure 41). NICD itself is a target for the proteasome (204,283,284). 
Substitutions at the S3 site of Notch1, such as Notch1 V1744L and Notch1 V1744G were 
reported to decrease Notch processing and to affect NICD stability by increasing its rate of 
degradation (285). However, a careful re-examintation showed that these mutants have 
the same rate of degradation as the wild type protein, while the processing rates of these 
mutants were still significantly lower as those of the wild type protein (286).  
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Figure 41: Schematic depiction of an hypothetical alteration of the cleavage site in Notch1 
produced by PS1 G382A and PS1 L383F. The amino acids of the TMD of Notch are depicted in 
orange. PS1 wt site of processing is depicted in blue whereas the hypothetical site of processing of 
the mutants is depicted in red. 
 
 
 
To investigate the possibility wether the NICD produced by the PS1 G382A and PS1 
L383F mutants are differently turned over by the proteasome than the NICD produced by 
PS1 wt, PS1/PS2 -/- MEF cells were transiently co-transfected with the cDNA encoding 
for F-NEXT and with the cDNAs encoding for PS1 wt, PS1 G382A, PS1 D385A and vector 
alone (figure 42) as well as with the H6X-tag versions of PS1 wt, PS1 D385A and PS1 
L383F (figure 43). Cells were treated with lactacystin, a well-characterized proteasome 
inhibitor (269) for 5 hours. Following transfection and inhibitor treatment, total cell lysates 
were analysed as before. β-Catenin was immunoblotted as independent control to monitor 
the increase in levels of β-catenin upon proteasome inhibitor treatment (figure 42 and 
figure 43, panel F) (287). All proteins were robustly expressed. As before, PS1 were 
endoproteolysed except for the PS1 D385A mutant and maturation of NCT was observed 
demonstrating correct γ-secretase complex formation (figure 42 and figure 43, panels A, B 
and C). As expected, PS1 wt, PS1 G382A and PS1 L383F mutants processed F-NEXT to 
NICD with significant difference in efficiency (figure 42 and figure 43 panels D and E). 
When PS1 wt, PS1 G382A and PS1 L383F were treated with the proteasome inhibitor, an 
increase in the holoprotein was observed (137) but not in the PS1NTF and PS1CTF as they 
form part of a stable and active γ-secretase complex (figure 42 and figure 43 panels B and 
C) (137). Upon proteasome inhibitor treatment, NICD levels were increased in PS1 wt, 
PS1 G382A and PS1 L383F mutants. The increase of NICD observed in PS1 G382A and 
PS1 L383F is, however, similar as the one observed for PS1 wt, suggesting that the 
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NICDs generated by the mutants are similarly degraded as PS1 wt (figure 42 and figure 
43, panels D and E). Therefore the reduced amount of NICD produced in the PS1 G382A 
and PS1 L383F mutants is most probably due to a reduced activity of the enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. PS1 G382A mutant does not miscleave the substrate. In panels A, B and C, lysates 
from cells transiently expressing the above PS constructs and F-NEXT as substrate were analysed 
by immunoblotting for γ-secretase components using N1660, PS1N and 3027 antibody. In Panel D, 
processing of F-NEXT was analysed by immunoblotting with antibody 9E10. Panel E, NICD was 
detected by cleaved Notch1 antibody. Panel F, β-catenin was analysed by anti-β-catenin antibody. 
γ-Secretase components were separated by 10% Tris-glycine-urea SDS-PAGE. F-NEXT and NICD 
were separated by 7% Tris-glycine SDS-PAGE as well as β-catenin.  
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Figure 43. PS1 L383F does not miscleave F-NEXT. Panels A, B and C, lysates from cells 
transiently expressing the indicated PS1 constructs and F-NEXT as substrate were analysed by 
immunoblotting for γ-secretase components, using N1660, PS1N and 3027 antibody. In Panel D, 
processing of F-NEXT was analysed by immunoblotting with antibody 9E10. Panel E, NICD was 
detected by cleaved Notch1 antibody. Panel F, β-catenin was analysed by anti-β-catenin antibody. 
γ-Secretase components were separated by 10% Tris-glycine-urea SDS-PAGE. F-NEXT and NICD 
were separated by 7% Tris-glycine SDS-PAGE as well as β-catenin. 
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4 Discussion 
 
In order to study the role of the N-terminal glycine of the GxGD motif in PS1 a 
mutagenesis approach was used. The N-terminal glycine was mutated to alanine, 
isoleucine, proline, tryptophan, lysine, and aspartate to cover a wide range of diverse side 
chains. Once the mutants were created the role of PS1 G382 in γ-secretase assembly and 
activity was studied. 
 
 
4.1 Most of the PS1 G382 mutants inhibit PS1 endoproteolysis 
 
As judged from the normal NCT maturation, γ-secretase complex assembly was found to 
be normal for all PS1 G382 mutants. Maturation of NCT only takes place when the γ-
secretase components are correctly assembled, allowing the complex to leave the ER and 
to traffic to the Golgi apparatus where NCT becomes fully mature by complex 
glycosylation (figure 15) (154,289-291). These data demonstrate that PS1 G382 mutants 
do not disturb γ-secretase assembly. Surprisingly, however, none of the PS1 G382 
mutants supports PS1 endoproteolysis with the exception of PS1 G382A (figure 15). 
Clearly, the impaired endoproteolysis is not due to an incorrect γ-secretase complex 
formation. Rather it is more likely that PS1 G382 mutants do not go endoproteolysis due 
to a structural change in the molecule that affects this autocatalytic mechanism. Similar 
observations have been made previously for other mutations in the GxGD motif like PS1 
G384K and PS1 G384D, in the PALP motif, in the TMD1 of PS, and in the C-terminus of 
PS which have been reported to impair this autocatalytic activity probably by distorting PS 
conformation (292-294). This result suggests that PS1 G382 is an important determinant 
for PS endoproteolysis. Only minor changes of this residue from glycine to alanine are 
accepted for PS endoproteolysis.  
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4.2 PS1 G382A has reduced γ-secretase activity possibly due to a 
distorted docking site 
 
4.2.1 PS1 G382 mutants are inactive regarding APP processing except 
PS1 G382A mutant 
 
Most PS1 G382 mutants do not support γ-secretase activity in APP processing. The only 
exception found was PS1 G382A, in both HEK/sw cells and in in vitro assays (figure 15 
and 17). The PS1 G382A mutant rescues the accumulation of APPCTFs observed in the 
aspartate mutant and can secrete Aβ to the conditioned media.  Nevertheless its activity is 
lower in comparison to PS1 wt (figure 15). Similar results were observed in vitro where no 
endogenous γ-secretase complex could interfere with the results as PS1 G382 γ-
secretase mutant complexes were isolated by immunoprecipitation against the Xpress 
epitope (figure 17) and in PS1/PS2 -/- MEF cells where PS1 G382A is able to process 
APP (figure 29). These results suggest that a minor change within this motif is accepted 
for APP processing. 
 
Because the PS1 G384A mutant alters the specificity of the γ-cleavage increasing Aβ42 
levels (148), it was investigated if the PS1 G382A mutant also alters the specificity of the 
γ-cleavage. Indeed, PS1 G382A increased Aβ38 and slightly Aβ42 production and 
produced a longer Aβ species, Aβ43 (figure 18 and figure 20). This suggests that the PS1 
G382A mutation may cause a conformational alteration in PS1, which effects an alteration 
of the specificity of the γ-cleavage.  
 
 
 
4.2.2 PS1 G382A has an altered response to NSAIDs 
 
It has been widely assumed that Aβ38 and Aβ42 production by γ-secretase are coupled 
since NSAIDs effect a decrease in Aβ42 and a concomitant increase in Aβ38 and vice 
versa (233,270). The PS1 G382A mutant can be regarded as an artificial FAD mutation as 
Aβ42 and Aβ43 levels are elevated in comparison to PS1 wt (figure 18 and 19). 
Surprisingly, from the three NSAIDs tested (sulindac sulfide, flurbiprofen and naproxen) 
and the lipid-regulating drug fenofibrate, only with sulindac sulfide and fenofibrate PS1 
G382A had a similar response as PS1 wt (figure 22 and 26). Interestingly, fenofibrate 
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markedly increased Aβ43 species production in PS1 G382A (figure 25 and figure 28). On 
the other hand, PS1 G382A had an altered response to flurbiprofen and naproxen 
compared to PS1 wt. For both NSAIDs, PS1 G382A can cause a decrease in Aβ38 and 
Aβ42 levels with a concomitant increase in Aβ40 levels (figure 22 and 26). Interestingly, 
naproxen, which was believed to be an inactive γ-secretase modulator (233), can cause a 
slightly increase in Aβ38 and Aβ37 levels in PS1 wt overexpressing cells (figure 26 and 
figure 27). This suggests that naproxen is a GSM only modulating the production of short 
species. Taken together, these data show that Aβ38 and Aβ42 production are not 
coupled. 
 
This uncoupled production has recently been also observed in FAD mutants of PS1 and 
for the PS2 FAD mutation N141I (277-279). Both studies showed that strong FAD 
mutations are partially insensitive to γ-secretase inhibitors and unresponsive to the Aβ42 
modulatory effect of NSAIDs (279,295,296). However, they still responded to the Aβ38 
modulatory effect of the NSAID investigated (277,278). 
 
Fluorescence resonance energy transfer (FRET) experiments have suggested that 
NSAIDs affect the conformation of PS and the proximity of APP and PS (237). In addition, 
FAD mutations have also been shown to alter the structure of the active site by changing 
the proximity of the PSNTF and PSCTF (237). It is then plausible that PS1 G382A mutant 
alters the PS conformation causing an alteration in the cleavage specificity of γ-secretase, 
thereby increasing the amount of Aβ38 Aβ42 and Aβ43 (Figures 18–20). This 
conformational change thereby may also affect the binding and modulation of γ-secretase 
by NSAIDs. Some NSAIDs modulate the γ-secretase activity of PS1 G382A but less 
efficient as in the wild type situation (sulindac sulfide and the lipid-regulating drug 
fenofibrate) whereas some other NSAIDs (flurbiprofen and naproxen) modulate the PS1 
G382A γ-secretase activity in a completely different way as for PS1 wt.  
 
The molecular mechanism of GSMs action on γ-secretase has not been elucidated yet. 
One possible mode of action can be that the GSMs slightly misplace the substrate in the 
catalytic center by changing PS conformation thus causing changes in the cleavage 
specificity of γ-secretase (see figure 44 panel B). In PS1 mutants, the substrate is likely 
already misplaced due to a distorted PS conformation (see figure 45 panel A). GSM 
treatment of PS1 mutants could further distort the conformation, depending on the 
particular GSM and the particular PS1 mutant present and gives rise to an additional 
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alteration of the cleavage specificity of the enzyme for the substrate (see figure 47 panel 
B). 
 
 
 
 
 
 
 
 
Figure 44. Schematic depiction of potential conformational changes of PS wt upon GSMs 
treatment. In green are the TMD carrying the critical aspartates. The substrate is depicted in 
orange. The normal placement of the substrate in the protease is shown (A). In response to GSMs, 
PS wt changes its conformation causing misplacement of the substrate (B). 
 
 
 
 
 
 
 
 
 
 
Figure 45. Schematic depiction of potential conformational changes of PS mutant in response to 
GSMs treatment. In green are the TMD carrying the critical aspartates. The substrate is depicted in 
orange. In A, in PS1 mutants the conformation of the protease is changed misplacing the substrate. 
In response to GSMs, PS mutants change their conformation further misplacing the substrate (B). 
 
 
 
4.2.3 PS1 G382A processes APP and Notch1-3 homologues but not 
Notch4 and CD44 
 
Because it was found that all PS1 G382 mutants (except PS1 G382A) did not allow APP 
processing, it was next investigated whether other substrates behaved similarly. PS1/PS2 
-/- MEF cells were used to further confirm the results obtained in section 3.1.1. In addition, 
PS1 G382 mutants undergo normal γ-secretase complex formation in PS1/PS2 -/- MEF 
cells as NCT maturation was observed. Again, however, except for the PS1 G382A 
mutant, no endoproteolysis was observed (figures 29,31,33,35,37 and 39) confirming the 
results obtained in HEK/sw cells (figure 15). In terms of γ-secretase activity PS1 G382A 
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mutant is able to cleave APP and Notch1-3 homologues although less efficient as PS1 wt 
(figures 29-36). On the other hand, strinkingly, PS1 G382A was unable to process Notch4 
and CD44 (figures 37-40) suggesting that for some substrates, a small side chain is 
accepted and their processing can occur (APP and Notch1-3). For some other substrates, 
however, (Notch4 and CD44), a glycine in position 382 is indispensable for their 
processing and not even a minor side chain change is accepted. These results point to a 
necessity to provide as less steric hindrance as possible in this region and suggests that 
this residue must be as small as possible to allow the accomodation of the many PS 
substrates, which all differ in their transmembrane domains, at the active site region. 
Because glycine does not have any lateral side chain, this amino acid minimizes possible 
steric hindrance effects allowing that all γ-secretase substrates can be efficiently bound 
and processed. 
 
 
4.2.4 NICD generated by PS1 G382A and PS1 L383F mutants have a 
similar proteasomal turn over 
 
The subtle change in the protein conformation due to the PS1 G382A mutation may affect 
the velocity of the enzyme causing a slow turn over of the substrate. In fact, this is the 
case as the processing of APP and Notch1-3 is somewhat diminished in the PS1 G382A 
mutant (see figure 17 and figures 29-36). Another mutation within the GxGD motif, the 
PS1 L383F mutant has been shown to strongly impair Notch processing (149). Because 
NICD is a substrate for proteosomal degradation, the observed reduction in both mutants 
could potentially be due to a miscleavage of the substrate at S3 exposing a new de-
stabilizing N-terminal residue of the NICD (figure 41). According to the N-end rule, the 
half-life of a protein is determined by the nature of its N-terminal amino acid, as a de-
stabilizing N-terminal residue will affect the rate of proteasomal degradation of the peptide 
(282). As observed in figure 42 and figure 43 an increase of NICD is detected upon 
lactacystin treatment in PS1 wt, PS1 G382A and PS1 L383F. The increase of NICD 
observed in the mutants is similar as the one observed for PS1 wt suggesting that the 
NICDs produced by these two PS1 mutants have a similar proteasomal turn over as the 
NICD produced by PS1 wt. This suggests that PS1 G382A and PS1 L383F do not 
miscleave the substrate in the S3-site but rather in the γ-site as both mutants changes the 
ratio of Aβ43/Aβ42 to Aβ40 (figure 18-20 and Yamasaki et al, unpublished observations). 
These results suggest that the reduction in the catalysis of the γ-secretase substrates 
observed in these two mutants of the GxGD motif is due to a reduced activity of the 
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enzyme. This reduced activity could be because the mutations influence the active site 
conformation thus slowing the catalysis. 
 
 
4.2.5  PS1 G382 may form part of the γ-secretase substrate docking 
site 
 
The slow turnover of the substrate by the PS1 G382 mutant may be also because the 
mutation affects the docking site thereby reducing the affinity of the enzyme for its 
substrate. Preliminary co-immunoprecipitation experiments, inactive PS1 G382 mutants 
have less substrate associated to the enzyme in comparison to an active site mutant (PS1 
D385A) (data not shown). It is very unlikely, however, that PS1 G382 γ-secretase mutants 
have an impact on the ability of NCT to bind the substrates because NCT (figure 46 blue) 
does only recognize the free amino terminal residue from shedded substrates (e.g. the 
APP CTFs) as first recoginition step (figure 46 panel B) (165). The shedded substrate is 
then transferred to the docking site in PS (2) (depicted in yellow) where it binds before the 
substrate translocates to the active site (depicted in red) where it is processed (4). Helical 
ten amino acid peptide inhibitors based on the TMD of APP were shown to inhibit γ-
secretase apparently by binding to its docking site (224). Interestingly, an extension of 
three extra amino acids resulted in an inhibition of γ-secretase by binding to its docking 
and active site (224). This result suggests that the docking and active site are very close, 
within a distance of three amino acids, and partially overlapping (224). In the case of the 
PS1 G382 mutants (figure 46 panel B), NCT also recognizes the shedded substrate (1) 
and transfers it to a distorted docking site (2). If the PS1 G382 mutants distort the docking 
site, the affinity of the enzyme for its substrate will be impaired (figure 46 panel B). In the 
case of the PS1 G382A mutant, the docking site is not extremely altered, therefore the 
enzyme retains affinity for some substrates allowing to a considerable extent their 
processing (APP, Notch1-3). For other substrates, the enzyme would not retain any 
affinity so they will dissociate from the enzyme and thus not being processed (Notch4 and 
CD44) (figure 46 panel B). The reason why for some substrates the PS1 G382A retain 
some affinity and not to some others is currently unclear and will need further studies to 
be solved.  
 
Recent evidence suggests that the GxGD motif has a dual role in PS. This motif 
contributes on one side to the catalytic function of the enzyme by the active site aspartate 
and the glycine preceding it (143-145)(148), and on the other side to substrate 
discrimination by the amino acid in position x (149). These two functions are probably 
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overlapping (149). Preliminary results suggest that this motif contributes to the substrate 
docking site. Changes within this motif will affect the proposed roles of the GxGD motif. 
PS has a variety of substrates with different transmembrane domains. In order to 
accommodate all of them at the active site region, the docking site must have certain 
sequence requirements. Since glycine’s side chain is a hydrogen atom, it is the optimal 
amino acid to minimize possible steric hindrance effects enabling that all γ-secretase 
substrates are effectively bound prior to their processing. 
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Figure 46. Schematic representation of the hypothetic substrate binding and processing in PS1 wt 
(panel A) and in PS1 G382 mutants (panel B). 
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4.3 Putative structural placement of PS1 G382  
 
Recently, the crystal structures of two intramembrane proteases have been elucidated, 
the rhomboid structure (297-301) and the S2P structure (302). These structures have 
shown that the substrate entry mechanism may be conserved in these intramembrane 
proteases. 
 
Rhomboid is an intramembrane serine protease (303) whose structure has been revealed 
to be a horseshoe structure (304) that allows the substrate to enter laterally to the active 
site for its processing. The active site is formed by α-helix 6 and α-helix 4. α-Helix 4 
carries the critical serine residue and is tilted inside within the membrane (297-301). For 
S2P, a horseshoe structure has been also observed allowing the substrate to enter 
laterally. The active site in S2P is formed by three α-helices, which are also tilted within 
the membrane. Interestingly, in α-helix 3 a putative dimerization motif is observed 
(AG/xxxN/S/G) which may help to stack these three helices together. This motif is also 
believed to form part of the active site as mutagenesis of the N-terminal glycine is 
predicted to perturb the conformation of the active site due to steric hindrance (302). 
 
 
 
 
 
 
 
 
 
 
Figure 47. Schematic model of a hypothetical horseshoe-like structure of PS (top view). The 
substrate (pink) will first bind to the docking site (DS) to which G382 (depicted in black) might 
contribute. From there, the substrate may enter laterally to the active site of PS (AS) where the 
critical aspartes (depicted in red) are located. 
 
 
 
It is possible and likely that the intramembrane proteases have a common substrate entry 
mechanism. Therefore, the substrates for PS can also enter laterally as the substrates for 
Rhomboid and S2P do (see figure 47). For being processed, the substrates must enter 
laterally, binding first to the docking site and then move to the active site. If PS1 G382 of 
the GxGD motif in PS plays a role in the docking site, the TMD7 is unlikely to be in a 
perfect helix conformation spanning the membrane, but more tilted inside the membrane. 
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If TMD7 is tilted inside the membrane, then glycine 382 of the PS1 GxGD motif is exposed 
more outside (see figure 48) being the first amino acid of the GxGD motif to have a 
contact with the substrate. This event will allow PS1 G382 to take part in the formation of 
the docking site for the substrate. If PS1 G382 forms part of the substrate docking site, it 
may allow conformational flexibility of the docking pocket and less steric impediments for 
the different TMDs of the many γ-secretase substrates due to the presence of the smallest 
possible side group: the hydrogen atom. Changes in this region, even subtle ones, will 
restrict the flexibility of the docking pocket and will provoke more steric hindrances for the 
substrates. These steric hindrances may affect the affinity of the enzyme for the substrate 
close to the active site such that some substrates can be processed while others not (see 
figure 46 panel B). Nevertheless, the internal structure of γ-secretase still has not been 
elucidated so it is not known whether the TMD7 of PS is indeed tilted inside the 
membrane or whether it has a funnel-like structure as it has been suggested by others 
(130). 
 
 
 
 
 
 
 
 
 
 
 
Figure 48. Schematic depiction of PS with TMD7 tilted inside the membrane. TMDs of PS molecule 
are depicted in red. TMD6 and TMD7 are depicted in green. Critical aspartates are shown in 
yellow. Substrate is depicted in orange. 
 
 
The N-terminal glycine of the GxGD motif is conserved in all GxGD aspartyl protease 
families and is also suggested in this study to be functionally conserved in SPP as its 
mutation significantly reduces the activity of the protease (data not shown). However, 
whether the N-terminal glycine mutations distort the active site enabling the activity or 
enabling the putative similar substrate docking site in SPP may need deeper studies.  
 
There are some exceptions found in the conserved GxGD motif within the TFPP family, in 
the bundle-forming prepilin peptidase (BfpP) from E.coli (248) and in the Archaea 
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Methanosphaera stadtmanae, Methanothermobacter thermautotrophicus, Pyrococcus 
abyssi, Pyrococcus furiosus, Pyrococcus horikoshii and Thermococcus kodakarensis  
(305). However, in these cases, the N-terminal amino acid found in the GxGD motif is an 
alanine again implying the importance for this region to have the less steric hindrance and 
is consistent with the findings reported here. As shown in this study, the side chain of 
alanine is a methyl group and the length of this methyl group is the maximal length 
tolerated for this residue. All of the larger side chains cause an inactivation of the enzyme. 
 
 
 
4.4 PS1 G382 may form part of a putative helix-packing motif 
 
Glycines residues that are present in the membrane-spanning helices usually do not 
disrupt the secondary structure and are known to support efficiently helix-packing in 
polytopic membrane proteins (306,307). Interestingly, PS1 and PS2 have a conserved 
helix-packing motif GxxxG in TMD7, of which PS1 G382 is the C-terminal residue. The 
GxxxG motif has been shown to promote helix-packing in polytopic membrane proteins as 
well as to promote dimerization (308). In general, a helix-packing motif requires a small 
side chain amino acid (glycine, alanine, serine, threonine or proline) followed by three 
aliphatic amino acids and finally another small side chain amino acid (309,310). This 
GxxxG motif has also been found in APP suggesting that APP can form a dimer. 
Interestingly, the replacement of the glycines in this motif lead to an attenuation of APP 
dimerization altering the γ-cleavage by reducing the levels of Aβ40 and Aβ42 but without 
altering the ε-cleavage (311,312). APH-1 also carries a GxxxG motif, which has been 
shown to be important for the stable association of APH-1 in the γ-secretase complex 
(313-316).  
 
It is maybe possible that PS1 G382 contributes to packing of TMD7. Alanine also supports 
the close packing of helical proteins (307), explaining why the alanine is tolerated in this 
position. The introduction of an alanine will thus create a GxxxA, which is a GxxxG-like 
motif, compatible with TMD packing (317). The close packing of two helices in polytopic 
membrane proteins opens up interhelical regions that become more loosely packed. 
These regions can contain polar residues and can provide the binding sites for substrates 
and ligands (307). So it might be, that due to the packing motif to which G382 might take 
part, a cavity or pocket is formed in which the substrates are pre-bound prior to its 
processing.  
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One has to note, however, that this GxxxG motif of TMD7 is not found in all the members 
of the PS family. In C.elegans, the PS homologues HOP-1 (homologue of PS 1) and SPE-
4 (spermatogenesis defective) do not have the GxxxG motif, whereas it is found in Sel-12 
(Suppressor/Enhancer of Lin-12) another C.elegans homologue. HOP-1 has a TxxxG 
motif, which is sometimes found in helix-packing motifs in a variety of proteins like 
receptor Erb-3 (318) and in EGFR and Ros (309). Furthermore, no helix-packing motif is 
found in SPP family members as they have a FxxxG (SPP, SPPL2b and SPPL3) or 
VxxxG motif (SPPL2a). SPP family members are believed to be active without any 
additional proteins (246). It might be, thus, that this motif is only present in proteins that 
form complexes with other proteins. This motif would be then needed for interaction the 
substrate APP that also has a GxxxG motif (312) or maybe is important for the complex 
association with APH-1 (313). On the other hand, proteins that are in a complex might 
need to be closer packed than proteins that work as monomer and are not part of a 
complex. Regarding PS, the insertion of a big side amino acid in this motif may avoid the 
close packing, disrupting the self-catalysis of PS and the active conformation, however, 
this would cause disrupt complex formation, which is not observed. 
 
 
 
4.5 The GxGD and PALP motif may be located close together in 
PS 
 
Apart from the conserved motif GxGD, PS has another conserved motif, the PALP motif in 
TMD9 (see figure 49). This motif comprises amino acid 433-436 of PS1. Interestingly, this 
motif is also found in all other GxGD-type aspartyl proteases, such as the SPP/SPPL and 
TFPP families, where a PxL motif is conserved (244,246). In PS1, mutations in the PALP 
motif impair the endoproteolysis and depending of the mutation inhibit γ-secretase activity 
(294). The PALP motif has been suggested to contribute to a stable active site 
conformation of PS because mutations in this motif do not allow the binding of a transition 
state analogue inhibitor (294). 
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Figure 49: Schematic depiction of the PS molecule showing the conserved GxGD and PALP 
motifs. 
 
 
Changes in the N-terminal proline (P433) of the PALP motif, result in an impairment of 
PS1 endoproteolysis (294) except for the PS1 P433A mutation. Interestingly, this mutant 
can also support APP and Notch1 processing (294). These observations are similar to 
PS1 G382A and PS1 P433A where only a small side chain of amino acid is tolerated for 
endoproteolysis and activity, suggesting that in both positions a very small side chain is 
required. Furthermore, both mutants behave similar to NSAIDs. PS1 433A and PS1 
G382A have a typical NSAID response to sulindac sulfide, whereas flurbiprofen 
decreases Aβ42 to the same extent as PS1 wt but strongly decreases Aβ38 levels 
(Tomioka et al, unpublished observation). 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Schematic depiction of the PS with a hypothetical structure of the last three 
transmembrane domains. TMD7 containing the GxGD motif is in green and TMD9 with its PALP 
motif is in blue. 
 
 
Although this PALP motif is found distant from the GxGD motif in the primary sequence, it 
might be close to the GxGD motif in the tertiary structure of PS (see figure 50). This would 
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be supported by the similar behaviours upon mutation of the motifs (294). This would 
suggest that both PALP and GxGD motifs are very close together. Furthermore, the PS1 
A431 of the PALP motif might form part of the helix-packing motif AxxxSxxxG (319). Thus, 
it is possible that due to the both helix-packing motifs found in TMD7 and TMD9 these two 
TMD are close together taking both part of the active site conformation of the complex. 
Changes in one of these two motifs might affect the conformation of the other, and vice 
versa distorting the active site conformation of PS in a similar way. 
 
Interestingly, a recent work has reported new results indicating that the GxGD motif and 
the PALP motif might be indeed close together, both forming part of the catalytic pore 
(320).  
 
 
4.6 Outlook 
 
Taken together, the mutational analysis data of the G382 residue in PS1 presented in this 
thesis, demonstrate the crucial importance of this glycine for the activity of γ-secretase. 
Preliminary results suggest this residue as a possible element of the substrate docking 
site. To further confirm that G382 forms part of the docking site of the protease, Co-IP 
experiments with substrates that are not cleaved in the PS1 G382A mutant could be 
performed in order to confirm whether these substrates are bound to the complex or not. It 
will be also very helpful to investigate the binding capacity of helical-peptide inhibitors that 
are believed to bind to the docking site of the substrate (224). If PS1 G382 is involved in 
the docking site formation, the binding of these helical-peptide inhibitors is expected to be 
altered.  
 
To further address the question why PS1 G382A mutant retains some affinity to certain γ-
secretase substrates and not to others, additional substrates should be analysed. This 
may also give information about the sequence requirements of the TMD of the different 
substrates to be able to be cleaved by the protease. 
 
Fluorescence resonance energy transfer experiments can be performed in order to 
investigate whether PS1 G382 mutants change the PS conformation by altering the 
distance between PS1CTF and PS1NTF as observed previously for FAD mutants. 
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To prove the slower rate of the mutant enzyme a kinetic study of the mutant enzyme 
should be performed. For these studies, purified γ-secretase and substrate are required. 
 
Finally, to further evaluate whether PS1 G382 also forms part of a helix-packing motif a 
mutagenesis approach should be used mutagenizing both glycines of the GxxxG motif to 
investigate if γ-secretase assembly is impaired or if an alteration of PS conformation is 
observed which might have repercussions in the catalytic activity of the enzyme. 
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5 Summary 
 
γ-Secretase catalyses the final processing step of the β-amyloid precursor protein (APP) 
and thereby generates the AD-causing amyloid β-peptide (Aβ) as well as the APP 
intracellular domain (AICD). Apart from APP, γ-secretase has more than 20 known 
substrates. These are type I membrane proteins that undergo ectodomain shedding to 
become a γ-secretase substrate. γ-Secretase is a multimeric complex formed of four 
essential subunits, presenilin (PS), nicastrin (NCT), anterior pharynx defective 1 (APH-1) 
and presenilin enhancer 2 (PEN-2). PS1 and PS2 are the catalytic subunit of γ-secretase 
and provide the catalytically active aspartates located in transmembrane domains (TMD) 
6 and 7. NCT has been shown to act as a γ-secretase substrate receptor by recognizing 
the free amino terminus of the shedded substrate. Following NCT binding, the substrate is 
believed to translocate to the postulated docking site that has been shown in PS1 to be 
within three amino acid distance to the critical aspartate in PS1 TMD7. PS is an unusual 
aspartyl protease, with a novel GxGD active site motif, which is also found in other 
aspartyl proteases such as SPP and TFPP. The functional characterization of the GxGD 
motif has only been partially addressed so far. Mutational analysis of the glycine 
neighbouring the critical aspartate and the amino acid in position x in PS1 have shown 
that this motif is important for the activity of the enzyme as well as for substrate 
(APP/Notch) selectivity. To further characterize this conserved motif an extensive 
mutational analysis of the N-terminal glycine was performed in PS1.  
 
The following results were obtained: 1) PS1 G382 is not critical for γ-secretase complex 
formation. All the PS1 G382 mutants investigated support normal γ-secretase complex 
formation as judged from the normal maturation of NCT that is observed for all PS1 G382 
mutants. Surprisingly, none of the PS1 G382 mutants could support endoproteolysis of 
PS1 except the PS1 G382A mutant. This shows that PS1 G382 is important for 
endoproteolysis of PS and that PS endoproteolysis requires a small side chain amino acid 
in this region of the enzyme. 
 
2) PS1 G382 mutants do not support APP cleavage with the exception of the PS1 G382A 
mutant, which is partially active and is capable of generating Aβ and AICD. Furthermore, 
PS1 G382A increases the generation of Aβ43 and is expected to be a FAD mutation if it 
occurrs in humans. Interestingly, however, also Aβ38 generation is increased. This 
suggests that PS1 G382A changes the PS conformation altering its cleavage specificity.  
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3) PS1 G382A has an altered response to NSAID treatment (non-steroidal anti-
inflammatory drugs), which have been shown to modulate γ-secretase activity by lowering 
Aβ42 species and increasing Aβ38 species. For some γ-secretase modulators (GSMs) 
PS1 G382A responds similar to PS1 wt regarding Aβ38 and Aβ42 modulation (sulindac 
sulfide and fenofibrate) whereas for other GSMs (flurbiprofen and naproxen), PS1 G382A 
has an altered response regarding Aβ38 and Aβ42 modulation. Furthermore, Aβ40 levels 
are increased by PS1 G382A when treated with flurbiprofen and naproxen. This implies 
that modulation of Aβ38 and Aβ42 generation by GSMs is not coupled as it was initially 
thought.  
 
4) PS1 G382 mutations have a strong impact on the processing of a number of γ-
secretase substrates. Notch1, Notch2 and Notch3 were partially processed by the PS1 
G382A mutant. Surprisingly, PS1 G382A did not support the processing of CD44 and 
Notch4 implicating that changes in this region are accepted for the processing of some but 
not for all the γ-secretase substrates. 
 
Taken together, the findings in this thesis demonstrate the importance of the GxGD motif 
in PS1. The conservation of the glycines in the motif in different intramembrane proteases 
might fulfil the role to restrain the steric hindrance close to the active site in order to allow 
catalysis of the different substrates. 
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